Compounds for the Treatment of Cancer

Novel compounds targeting estrogen receptors in breast cancer provide a promising treatment approach by reducing receptor expression and inhibiting tumor growth, addressing the limitations of current therapies.

JP2024542821APending Publication Date: 2024-11-15KASHIV BIOSCIENCES LLC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024533823
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-06
Filing Date
2022-05-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

There is an unmet need for effective treatments for breast cancer, particularly in addressing hormone receptor-positive breast cancer that has progressed after anti-estrogen therapy, as current therapies like tamoxifen, aromatase inhibitors, and CDK inhibitors have limitations.

Method used

Development of novel compounds and pharmaceutical compositions that include specific chemical structures, such as those described by formulas I through XVI, which can be administered in various forms to treat breast cancer, targeting estrogen receptors and potentially inhibiting their function.

Benefits of technology

The novel compounds demonstrate cytotoxic effects on breast cancer cells, reducing estrogen receptor expression and tumor growth, offering a potential alternative to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542821000001_ABST
    Figure 2024542821000001_ABST
Patent Text Reader

Abstract

The present invention relates to novel compounds or pharma- ceutically acceptable salts thereof that are useful in the treatment of cancer. The present disclosure also relates to pharmaceutical compositions of the novel compounds and methods of using them to treat benign or malignant diseases of the breast or reproductive tract, prostate cancer, or endometrial cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to novel compounds and methods for their preparation. The disclosure also relates to pharmaceutical compositions of the novel compounds and methods for treating breast cancer therewith. [Background technology]

[0002] Cancer is one of the leading causes of death and concern worldwide. Breast cancer is one of the most common cancers among women in the United States. Once breast cancer develops, the cancer cells can spread (metastasize) to other parts of the body and become life-threatening. Breast cancer metastasizes when it grows in tissues near the breast. Cancer cells can also spread by entering the blood or lymphatic system.

[0003] Treatments for breast cancer include hormone therapy, chemotherapy, monoclonal antibody therapy, and chemotherapy. Breast cancers are identified by the presence of estrogen receptors (ER+) and progesterone receptors (PR+) on their surface (sometimes collectively referred to as hormone receptors). These ER+ cancers can be treated with drugs that block the receptors, such as tamoxifen, or with aromatase inhibitors, such as anastrozole or letrozole, that block the production of estrogen. Fulvestrant is an estrogen receptor antagonist for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women whose disease has progressed after anti-estrogen therapy.

[0004] CDK (cyclin-dependent kinase) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are also prescribed for breast cancer in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer.

[0005] However, there remains an unmet need in the treatment of breast cancer. Accordingly, it is an object of the present invention to provide novel compounds or salts thereof that are useful in the treatment of breast cancer. Summary of the Invention

[0006] In one embodiment, the present invention relates to compounds of formula I, their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates: [ka] During the ceremony; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals; wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbons to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, in which one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0007] In one embodiment, the present invention relates to a compound of formula (IA), a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] During the ceremony; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbons can be a single bond or a double bond depending on the substituents selected.

[0008] In one embodiment, the present invention relates to compounds of formula A, their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Here, R'1 is an optionally substituted heterocycloalkyl, heteroaryl, and [ka] wherein one or more of the substituents on the optionally substituted heterocycloalkyl, heteroaryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl, and aryl groups, where one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups, where one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0009] In one embodiment, the present invention relates to compounds of formula B, their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] where R1' is selected from: [ka] wherein R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl and aryl groups; wherein the one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; [ka] (hereinafter referred to as "solid line ◯") represents an aromatic ring; X is independently N, O, S, [ka] Selected from; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms a double bond; or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0010] In one embodiment, the present invention relates to compounds of formula C, their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] wherein R'1 is selected from: [ka] where R'2 is selected from: [ka] The solid circle represents an aromatic ring; [ka] (hereafter referred to as "dashed circle") represents saturated, partially unsaturated, or fully unsaturated ring: X is independently N, O, S, [ka] Selected from; Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"5, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R"4 and R"5, taken together with the atoms to which they are attached, form an oxo bond; [ka] Form.

[0011] In another embodiment, the present invention relates to a pharmaceutical composition comprising the novel compounds, their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates; and a pharma- ceutically acceptable excipient.

[0012] The pharmaceutical compositions of the present disclosure may be in any form known to those skilled in the art. The pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, or via an implanted reservoir, preferably orally, or by injection.

[0013] In another embodiment, the present invention provides the use of a compound of the present invention in the preparation of a pharmaceutical formulation, as described herein, for the treatment of a benign or malignant disease of the breast or reproductive tract. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 depicts the mean ± SD plasma concentration-time profiles following a single oral dose of Compound 121 in female CD-1 mice. [Diagram 2] Figure 2 depicts the cytotoxic effect of compound 121 on human breast cancer MCF-7 cells: the graph was plotted using Graph Pad Prism-9 with concentration on the X-axis and viability on the Y-axis. Each point on the curve corresponding to a test concentration represents the mean + / - SEM of triplicates. [Diagram 3] Figure 3 shows the effect of Compound 121 on uterine weight (Wet): Data are expressed as mean ± SEM n = 3-8, *p < 0.0001, E2 vs. treatment One Way ANOVA followed by Dunnett's multiple comparison test. Mean tumor volume ± SD for vehicle and test compound. PO: oral administration, E2; 17α-ethynylestradiol. [Figure 4] Figure 4 shows the effect of Compound 121 on MCF7 tumor-bearing nude mice. Mean tumor volumes ± SD for vehicle and test compound. Comparison of tumor volume measurements was performed by two-way ANOVA. [Diagram 5] FIG. 5 depicts the mean plasma concentration time profiles following single oral doses of Compound 121 and fulvestrant in cynomolgus monkeys. [Figure 6] Figure 6 depicts the cytotoxic effect of compound Ia on human breast cancer MCF-7 cells: the graph was plotted using Graph Pad Prism-9 with concentration on the X-axis and viability on the Y-axis. Each point on the curve corresponding to a test concentration represents the mean + / - SEM of triplicates. [Figure 7]Figure 7 represents the cytotoxic effect of compound I-bh on human breast cancer MCF-7 cells: the graph was plotted using Graph Pad Prism-9 with concentration on the X-axis and viability on the Y-axis. Each point on the curve corresponding to a test concentration represents the mean + / - SEM of three replicates. [Figure 8] Figure 8 shows the effect of compound I-bh on ERα expression in human breast cancer MCF-7 cell line: N=2 per group, data shown as mean±SEM. ##p<0.001 vs.vehicle, ***p<0.001 vs.vehicle. One Way ANOVA, Dunnett's Post Test, percentages are the inhibition rates of ERα expression in hMCF7 cell line by treatments compared with each vehicle. [Figure 9] Figure 9: Effect of Compound Ia on ERα expression in human breast cancer MCF-7 cell line: N=2 per group, data shown as mean ± SEM. ###p<0.001 vs. Vehicle ***p<0.001, **p<0.01, *p<0.05 vs. Vehicle One Way ANOVA, Dunnett's Post Test. The percentages shown are the inhibition rates of ERα expression in hMCF7 cell line by treatments compared to the respective vehicles. [Figure 10] FIG. 10 depicts the mean time versus plasma concentration of Compound Ia following oral administration of Compound Ia (10 mg / Kg) to rats. [Figure 11] FIG. 11 depicts the mean time versus plasma concentration of Compound I-bh following oral administration of Compound I-bh to rats (10 mg / Kg). [Figure 12] Figure 12 shows the effect of compound Ia on nude mouse MCF7 tumors. Mean tumor volumes ± SD for vehicle and test compound. Comparison of tumor volume measurements was performed by two-way ANOVA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The terms "a" and "an" do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item.

[0016] As used herein, the term "about" when referring to a measurable value is meant to encompass a variation of ±10%, preferably ±5%, more preferably ±1%, and even more preferably ±0.1% from the stated value.

[0017] The term "cancer" refers to diseases including solid cancers, lymphomas, and leukemias. Examples of various types of cancer include, but are not limited to, breast cancer, lung cancer, ovarian cancer, prostate cancer, endometrial cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, thyroid cancer, pleural cancer, pancreatic cancer, uterine cancer, cervical cancer, testicular cancer, anal cancer, bile duct cancer, gastrointestinal carcinoid tumors, esophageal cancer, gallbladder cancer, appendix cancer, and small intestine cancer, gastric cancer, central nervous system cancer, skin cancer, choriocarcinoma, head and neck cancer, blood cancer, osteogenic sarcoma, fibrosarcoma, neuroblastoma, glioma, melanoma, B-cell lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, small cell lymphoma, large cell lymphoma, monocytic leukemia, myeloid leukemia, acute lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma.

[0018] As used herein, the term "alkyl" refers to a straight-chain or branched saturated aliphatic radical having 1 to about 10 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl, and the like.

[0019] As used herein, the term "haloalkyl" refers to an alkyl group as defined above, containing at least one carbon atom substituted with at least one halo group. As used herein, the "haloalkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, isobutyl and n-butyl, which are independently substituted with one or more halo groups, such as fluoro, chloro, bromo and iodo. Examples of haloalkyl include, but are not limited to, -CH2Cl, -CHCl2, -CC13, -CH2F, -CHF2, -CF3, etc.

[0020] The term "alkenyl" refers to a straight or branched chain hydrocarbon having 2 to 10 carbon atoms with at least one carbon-carbon double bond. Alkenyl groups can have any suitable number of double bonds, including but not limited to 1, 2, 3, 4, 5 or more. In one embodiment, alkenyl groups include ethenyl (-CH=CH2), 2-propenyl (allyl, -CH2-CH=CH2), and the like.

[0021] The term "alkynyl" refers to alkynyl groups having from 2 to 10 carbon atoms and having at least 1 to 2 sites of alkynyl unsaturation, including ethynyl (-C=CH), propargyl (-CH2-C=CH), 1-butenyl, 2-butenyl, isobutenyl, butadienyl, and the like.

[0022] The term "cycloalkyl" refers to a saturated carbocyclic group having from 3 to 10 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl). Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.

[0023] The term "heterocycle" refers to an organic compound that includes a ring structure that includes an atom other than carbon, such as sulfur, oxygen, or nitrogen, as part of the ring. The ring structure may be substituted with multiple heteroatoms selected from sulfur, oxygen, or nitrogen. The ring may be a saturated, partially saturated, or unsaturated ring structure, including "heterocycloalkyl" and "heteroaryl."

[0024] The term "heterocycloalkyl" refers to a C-C alkyl group as defined above, in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S, or N. 10It refers to a cycloalkyl group, for example, a saturated heterocycloalkyl group includes aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl.

[0025] The term "aryl" refers to a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing from 6 to 14 carbon atoms in which at least one ring is aromatic in nature, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalenyl, indanyl, and the like.

[0026] The term "heteroaryl" refers to a monocyclic or fused bicyclic ring containing from 5 to 14 atoms, in which at least one ring is aromatic in nature and contains at least one heteroatom selected from N, O, or S. Examples include pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, benzoquinolyl, and the like.

[0027] The term "bicyclic" refers to a compound having two linked rings. Bicyclic compounds can be carbocyclic or heterocyclic. Both rings can further be aliphatic or aromatic or a combination of aliphatic and aromatic.

[0028] The term "spirocyclic" refers to a compound in which the two rings share only a single atom, the spiroatom, which is usually a quaternary carbon. Spirocyclic compounds can be carbocyclic or heterocyclic.

[0029] The term "bridged bicyclic" refers to a compound having two rings that share three or more atoms, and the two bridgehead atoms are separated by a bridge containing at least one atom. A bridged bicyclic compound may be carbocyclic or heterocyclic.

[0030] "Fused / fused" as used herein refers to a compound in which two rings share two adjacent atoms. In other words, the rings share one covalent bond.

[0031] The term "halogen" refers to chlorine, iodine, fluorine and bromine.

[0032] As used herein, the term "leaving group" or "L" or "L1" can be defined as a portion of a substrate that is cleaved by the action of a nucleophile. Examples of leaving groups include, but are not limited to, halogens (F, CI, Br, I), tosylates, mesylates, triflates, acetates, hydroxyls, camphorsulfonates, aryloxides, aryloxides, and the like.

[0033] The term "alkoxy" refers to an --O-alkyl group.

[0034] The term "alkoxyalkyloxy" refers to the group (alkyl-O-alkyl-O-).

[0035] The term "alkoxycarbonyloxy" refers to the group (alkyl-O-CO-O-).

[0036] The term "phosphate" refers to -O-PO(OH)2.

[0037] The term "phosphonyl" refers to -PO3H2.

[0038] The term "alkyl phosphate" refers to (-alkyl-O-PO(OH)2).

[0039] The term "hydroxyalkylamino" refers to (-NH-alkyl-OH).

[0040] The term “halo” or “halogen” refers to F, Cl, Br, and I.

[0041] The term "fully unsaturated" refers to an aromatic group.

[0042] The term "amino acid" as used herein refers to two stereoisomers, designated "D" and "L". The D and L forms of amino acids have identical physical properties and chemical reactivity, but rotate the plane of plane polarized light equally, but in opposite directions, and react at different rates with asymmetric reagents. All natural amino acids in proteins are in the L form. Amino acids include lysine, valine, tryptophan, phenylalanine, methionine, leucine, threonine, isoleucine, arginine, histidine, tyrosine, carnitine, serine, glutamine, aspartic acid, proline, glycine, cysteine, alanine, and glutamic acid. Amino acids may exist as "D" or "L" enantiomers.

[0043] The term "C(O)-amino acid" refers to an amino acid bonded to a carbonyl group via an amide or ester bond, more preferably via an amide bond.

[0044] The term "optionally" means that the event or circumstance described thereafter may or may not occur, and the description includes cases where the event or circumstance occurs and cases where it does not occur.

[0045] The term "pharmacologically acceptable carrier" of "pharmacologically acceptable excipient" refers to a non-toxic carrier that may be administered to a patient, together with a compound of the invention, and which does not destroy the pharmacological activity thereof.

[0046] The term "pharmaceutically acceptable excipient" includes vehicles, adjuvants, or diluents, or other auxiliary substances conventionally used in the art that are readily available to the public. For example, pharmaceutically acceptable excipients include pH adjusting and buffering agents, tonics, stabilizers, wetting agents, and the like.

[0047] As used herein, the term "salt" refers to acid or base salts of the compounds of the present invention. Salts of basic compounds are salts formed with mineral acids, organic carboxylic acids, organic sulfonic acids, and the like. Examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts of acidic compounds are formed with bases, i.e., cationic species such as alkali and alkaline earth metal cations, e.g., sodium, lithium, potassium, calcium, magnesium ions, ammonium cations, e.g., ammonium, trimethylammonium, diethylammonium, and the like. Salts of acidic compounds are formed with organic bases, i.e., tromethamine and meglumine.

[0048] The term "subject" generally includes any subject, such as rodents, non-rodents, mammals (e.g., humans, dogs, cats, horses, cattle, cloven-hoofed animals, rabbits, etc.), adults or children. The subject used may be healthy or may be one for which treatment of a disorder is desired. As used herein, the terms "subject" and "patient" may be used interchangeably.

[0049] The compounds of the present invention contain one or more asymmetric carbon atoms and therefore occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.All such isomeric forms of these compounds are expressly included in the present invention.Each stereogenic carbon may be in the R or S configuration.

[0050] As used herein, the term "deprotecting agent" includes, but is not limited to, hydrogen and palladium on carbon (H, Pd / C), ammonium formate and palladium on carbon (HCOΟΝΗ, Pd / C), palladium hydroxide on hydrogen and carbon (H, Pd(OH) / C), combinations of Pd / C and Pd(OH) / C, and acids such as hydrochloric acid, hydrobromic acid, and the like.

[0051] For purposes of the present invention, the term "substituted" shall be understood to include the addition or replacement of one or more atoms contained within a functional group or compound with one or more different atoms.

[0052] Unless otherwise constrained by the definition of the particular substituent, the above-listed groups, such as groups such as "alkyl", "alkenyl", "alkynyl", "heterocycle", "cycloalkyl", "heterocycloalkyl", "aryl", "bicyclic", "spirocyclic", "bridged bicyclic", and "heteroaryl", may be optionally substituted with one or more substituents selected from the group consisting of radicals such as "C1-C8-alkyl", "C2-C8-alkenyl", "C2-C8-alkynyl", "cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "amino", "alkylamino", "dialkylamino", "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "alkoxyalkyloxy", "alkoxycarbonyloxy", "carbamate", "sulfinyl", "sulfonyl", "alkoxy", "sulfanyl", "halogen", "carboxy", "haloalkyl", "cyano", "hydroxy", "mercapto", "nitro", "phosphate", "oxo", "alkylphosphate". The one or more substituents are selected from 1 to 10 in number; more preferably 1 to 5 in number. In one embodiment, the radical is optionally further substituted with 1 to 3 substituents selected from "C1-C8-alkyl", "C2-C8-alkenyl", "C2-C8-alkynyl", "cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "amino", "alkylamino", "dialkylamino", "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "alkoxyalkyloxy", "alkoxycarbonyloxy", "carbamate", "sulfinyl", "sulfonyl", "alkoxy", "sulfanyl", "halogen", "carboxy", "haloalkyl", "cyano", "hydroxy", "mercapto", "nitro", "phosphate", "oxo", and "alkylphosphate".

[0053] The term "oxidizing agent" as used herein includes, but is not limited to, reagents such as pyridinium dichromate (PDC), pyridinium chlorochromate (PCC), Dess-Martin peridinane (DMP), 2-rhodoxybenzoic acid, tetrapropylammonium perthenate (ΤΡΑΡ) 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO), sodium dichromate, phosphorus pentachloride, phosphorus trichloride, hydrogen peroxide, tert-butyl hydroperoxide (TBHP), iron(III) nitrate nonhydrate, sodium hypochlorite, sulfur trioxide pyridine complex, chromium(VI) oxide, cerium(IV) ammonium nitrate, manganese(IV) oxide, manganese(II) nitrate tetrahydrate, rhodium(III) chloride hydrate, dipyridine chromium trioxide, barium(VI) ferrate, barium permanganate, potassium permanganate, ruthenium(IV) oxide, and cerium(IV) ammonium sulfate. Examples of oxidation reaction names include, but are not limited to, Swern oxidation, Jones oxidation, Oppenauer oxidation, pfitzer-Moffatt oxidation, Parikh-Doering oxidation, Albright-Goldman oxidation, Corey-Kim oxidation, and Collins reagent.

[0054] The base used in the present invention can be an inorganic base and an organic base. Examples of organic bases include, but are not limited to, amines such as diisopropylethylamine, triethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), imidazole, N,N-dimethylaniline, N,N-dimethylaminopyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), or mixtures thereof. Examples of inorganic bases include, but are not limited to, carbonates, bicarbonates, hydroxides, or phosphates of alkali or alkaline earth metals such as potassium carbonate, sodium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium phosphate, sodium phosphate; hydrides such as sodium hydride, lithium hydride, or potassium hydride; alkoxides such as sodium or potassium methoxide or ethoxide, tert-butoxide, or mixtures thereof.

[0055] In this specification, the term "solvent" refers to, but is not limited to, nitriles such as acetonitrile, propionitrile, butyronitrile, isobutyronitrile, etc.; ethers such as dioxane, diethyl ether, diisopropyl ether, tetrahydrofuran, dimethoxyethane, etc.; hydrocarbons such as toluene, xylene, hexane, cyclohexane, etc.; chlorinated hydrocarbons such as methylene chloride, diethylene chloride, carbon tetrachloride, etc.; hydrocarbons such as toluene, xylene, hexane, heptane, cyclohexane, etc.; chlorinated hydrocarbons such as methylene chloride, ethylene dichloride, carbon tetrachloride, chloroform, chlorobenzene, etc.; polar aprotic solvents such as N,N-dimethylformamide (DMF), dimethylacetamide (DMAc), dimethylsulfoxide (DMSO), etc., or mixed solvents thereof.

[0056] The novel compounds of the present invention can be used in conventional solid or liquid pharmaceutical forms, such as tablets, capsules, powders, granules, solutions, injections, powders, etc. For this purpose, the novel compounds of the present invention are processed with conventional pharmaceutical excipients, such as binders, bulking agents, preservatives, disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release retardants, antioxidants and / or propellant gases.

[0057] In one embodiment, the compounds of this invention are administered in combination therapy with other agents, which may be administered sequentially or simultaneously to a patient. Alternatively, a pharmaceutical composition according to this invention may be comprised of a combination of a compound of this invention and another therapeutic agent.

[0058] In one embodiment, the present invention relates to a compound of formula I; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof selected from: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals; wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbons to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally being joined by one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] , R 17 is an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0059] In one embodiment, the present invention relates to compounds of formula I; their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; A is selected as -O-R2, where R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbons to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0060] In one embodiment, the present invention relates to a compound of formula (IA), a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected.

[0061] In one embodiment of the present invention, the bicyclic compound may be selected from the group consisting of: [ka] [ka]

[0062] In one embodiment, the bicyclic compound is optionally substituted with a radical selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, haloalkyl, cyano, hydroxy, mercapto, nitro, phosphate, oxo, alkylphosphate. In one embodiment, the bicyclic compound can be attached via a carbon atom or a nitrogen atom.

[0063] In one embodiment of the present invention, the spirocyclic compound may be selected from the group consisting of: [ka]

[0064] In one embodiment, the spirocyclic compound is optionally substituted with a radical selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, haloalkyl, cyano, hydroxy, mercapto, nitro, phosphate, oxo, alkylphosphate. In one embodiment, the spirocyclic compound can be attached via a carbon atom or a nitrogen atom.

[0065] In one embodiment of the present invention, the bridged bicyclic compound may be selected from the group consisting of: [ka]

[0066] In one embodiment, the bridged bicyclic compound is optionally substituted with a radical selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, phosphate, oxo, alkylphosphate. In one embodiment, the bridged bicyclic compound can be attached through a carbon atom or a nitrogen atom.

[0067] In one embodiment, the present invention relates to compounds of formula II; their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbons to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0068] In one embodiment, the present invention relates to a compound of formula III; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein X and A have the same meaning as given for the compound of formula (II).

[0069] In one embodiment, the present invention relates to a compound of formula IV; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein Y and A have the same meaning as given for the compound of formula (II).

[0070] In one embodiment, the present invention relates to a compound of formula V; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11may be substituted at any position substitutable by a radical, where one or more R 11 The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0071] In one embodiment, the present invention relates to a compound of formula V; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; A is selected as -O-R2, where R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0072] In one embodiment, the present invention relates to a compound of formula VI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below; i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0073] In one embodiment, the present invention relates to a compound of formula VII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein X and A have the same meaning as given for the compound of formula (VI).

[0074] In one embodiment, the present invention relates to a compound of formula VIII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein Y and A have the same meaning as given for the compound of formula (VI).

[0075] In one embodiment, the present invention relates to a compound of formula IX; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11may be substituted at any position substitutable by a radical, where one or more R 11 The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0076] In one embodiment, the present invention relates to a compound of formula X; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0077] In one embodiment, the present invention relates to a compound of formula XI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein X and A have the same meaning as given for the compound of formula (X).

[0078] In one embodiment, the present invention relates to a compound of formula XII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein Y and A have the same meaning as given for the compound of formula (X).

[0079] In one embodiment, the present invention relates to a compound of formula XIII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11may be substituted at any position substitutable by a radical, where one or more R 11 The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0080] In one embodiment, the present invention relates to a compound of formula XIV; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below; i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0081] In one embodiment, the present invention relates to a compound of formula XV; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein X and A have the same meaning as given for the compound of formula (XIV).

[0082] In one embodiment, the present invention relates to a compound of formula XVI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein Y and A have the same meaning as given for the compound of formula (XIV).

[0083] In one embodiment, the present invention relates to a compound of formula XVII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11may be substituted at any position substitutable by a radical, where one or more R 11 The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0084] In one embodiment, the present invention relates to a compound of formula XVII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of i) to ix) below: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 where R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0085] In one embodiment, the present invention relates to a compound of formula XIX; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein X and A have the same meaning as given for the compound of formula XVIII.

[0086] In one embodiment, the present invention relates to a compound of formula XX; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein Y and A have the same meaning as given for the compound of formula XVIII.

[0087] In one embodiment, the present invention relates to a compound of formula XXI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 wherein R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11may be substituted at any position substitutable by a radical, where one or more R 11 The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0088] In one embodiment, the present invention relates to a compound of formula XXII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 wherein R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11 may be substituted at any position substitutable by a radical, where one or more R 11The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0089] In one embodiment, the present invention relates to a compound of formula XXIII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein X and A have the same meaning as given for the compound of formula XXII.

[0090] In one embodiment, the present invention relates to a compound of formula XXIV; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] wherein Y and A have the same meaning as given for the compound of formula XXII.

[0091] In one embodiment, the present invention relates to a compound of formula XXV; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Where; A is, [ka] or -O-R2, where R1 is selected from hydrogen or alkyl; R2 is independently selected from the group consisting of: i) [ka] wherein R3 is selected from NH2, NHR4, or NR5R6; R4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 and R6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R5 and R6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally substituted at substitutable positions with one or more R7 radicals. wherein one or more R7 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [ka] where R8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR9R 10 wherein R9 and R 10 taken together with the carbon to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to four carbon atoms are replaced by heteroatoms selected from the group consisting of O, S or N, the ring optionally containing one or more R 11may be substituted at any position substitutable by a radical, where one or more R 11 The radical is independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [ka] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [ka] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [ka] Here, R 14 teeth, [ka] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [ka] Here, R 15is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [ka] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [ka] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

[0092] In one embodiment, the present invention relates to a compound of formula XXVI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituent attached to the carbon can be a single bond or a double bond depending on the selected substituent. a is selected from carbon or nitrogen; Q is selected from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, thioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl.

[0093] In one embodiment, the present invention relates to a compound of formula XXVII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single bond or a double bond depending on the substituents selected; wherein R5 and R6, together with the nitrogen to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocycle, substituted at substitutable positions with one or more R7 radicals, wherein the one or more R7 radicals are independently selected at each occurrence from the group consisting of substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, phosphonyl, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl, and substituted alkyl. In one embodiment, one or more of the substituents on the radical R7 are further substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, phosphate, alkylphosphate; or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0094] In one embodiment, the present invention relates to a compound of formula XXVIII; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; S is selected from O, C or N; and wherein R7 is selected from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heterocycloalkyl, thioalkyl, arylcarbonyl, arylcarbonyl, alkoxyalkyl.

[0095] In one embodiment, the present invention relates to a compound of formula XXIX, a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single bond or a double bond depending on the substituents selected; R4' is selected from hydrogen and optionally substituted alkyl. R4 is selected from the group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

[0096] In one embodiment, the optionally substituted substituents on R4 and R4' are selected from the group consisting of radicals such as C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, dialkylaminoacyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, haloalkyl, cyano, hydroxy, mercapto, nitro, phosphate, oxo, alkylphosphate, and the like.

[0097] In one embodiment, the present invention relates to a compound of formula XXX; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single bond or a double bond depending on the substituents selected; d is selected from carbon or nitrogen; 15 and R 16 taken together form an optionally substituted carbocyclic or heterocyclic structure; m and n each independently is 1 to 3.

[0098] In one embodiment, the spirocyclic compound of formula XXX is optionally substituted with substituents selected from the group consisting of alkylalkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, and alkoxyalkyl.

[0099] In one embodiment, the present invention relates to a compound of formula XXXI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; D is selected from an optionally substituted bicyclic, spirocyclic or bridged bicyclic compound, wherein the attachment of the bicyclic, spirocyclic or bridged bicyclic compound is through either a carbon atom or a nitrogen atom.

[0100] In one embodiment, the optional substituents on D may be selected from the group consisting of alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl.

[0101] In one embodiment, the present invention provides a novel compound synthesized and isolated in pure form. In one embodiment, the purity of the isolated novel compound is about 80% to about 80%. In one embodiment, the purity of the isolated novel compound is selected from the group consisting of about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.5%.

[0102] In another embodiment, the compound of the present invention may further be delivered in the form of a pharmaceutical composition comprising the compound of the present invention; Pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof.

[0103] In another embodiment, the present invention relates to a pharmaceutical composition comprising at least one compound of formula selected from formula I-XXXI, a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and at least one pharma- ceutically acceptable excipient. In one embodiment, the novel compound of the pharmaceutical composition has at least one compound of formula I, formula IA, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV, formula XV, formula XVI, formula XVII, formula XVIII, formula XIX, formula XX, formula XXI, formula XXII, formula XXIII, formula XXIV, formula XXV, formula XXVI, formula XXVII, formula XXVIII, formula XXIX, formula XXX, and formula XXXI, a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. In one embodiment, the present invention relates to a pharmaceutical composition comprising at least one compound of the present invention; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and at least one pharma- ceutically acceptable excipient.

[0104] The pharmaceutical compositions of the present disclosure may be in any form known to those of skill in the art. The pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, or via an implanted reservoir, preferably orally or by injection.

[0105] For example, in some embodiments, a pharmaceutical composition comprising a desired product is formulated for oral delivery, hi one embodiment, a pharmaceutical composition comprising at least one compound is delivered via a dosage form selected from the group consisting of a concentrate, a dry powder, a tablet, a liquid, a capsule, a pellet, an emulsion, or a tablet.

[0106] In one embodiment, the present invention provides a pharmaceutical composition comprising a pharma- ceutically acceptable excipient selected from a carrier, a binder, a diluent, a filler, a preservative, a disintegrant, a flow regulator, a plasticizer, a wetting agent, a dispersant, an emulsifier, a solvent, and an antioxidant.

[0107] The compounds of the present invention have anti-cancer activity. In one embodiment, the present invention provides compounds useful for the treatment of cancer.

[0108] In another embodiment, the present invention provides a compound for the treatment of benign or malignant disease of the breast or reproductive tract, prostate cancer, or endometrial cancer. In one embodiment, the benign or malignant disease of the breast is breast cancer.

[0109] In another embodiment, the present invention provides the use of a compound of the present invention in the preparation of a pharmaceutical formulation as described herein for the treatment of benign or malignant diseases of the breast or reproductive tract, prostate cancer or endometrial cancer.

[0110] In another embodiment, the present invention provides novel compounds useful in the treatment of estrogen-dependent indications such as breast cancer and gynecological disorders such as endometriosis.

[0111] In one embodiment, the present invention provides a method for treating cancer, comprising administering to a subject a compound of at least one formula selected from formula I to formula XXXI. In one embodiment, the present invention provides a method for treating cancer, comprising administering to a subject a compound of at least one formula selected from formula I, formula IA, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV, formula XV, formula XVI, formula XVII, formula XVIII, formula XIX, formula XX, formula XXI, formula XXII, formula XXIII, formula XXIV, formula XXV, formula XXVI, formula XXVII, formula XXVIII, formula XXIX, formula XXX and formula XXXI; their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates. In one embodiment, the present invention provides a method for treating cancer, comprising administering to a subject at least one compound of the present invention.

[0112] In one embodiment, the present invention provides a method for treating a benign or malignant disease of the breast or reproductive tract, comprising administering to a subject a compound of at least one formula selected from Formulae I-XXXI. In one embodiment, the present invention provides a method for treating a benign or malignant disease of the breast or reproductive tract, comprising administering to a subject a compound of at least one formula selected from Formula I, Formula IA, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, Formula XII, Formula XIII, Formula XIV, Formula XV, Formula XVI, Formula XVII, Formula XVIII, Formula XIX, Formula XX, Formula XXI, Formula XXII, Formula XXIII, Formula XXIV, Formula XXV, Formula XXVI, Formula XXVII, Formula XXVIII, Formula XXIX, Formula XXX, and Formula XXXI; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0113] In one embodiment, the present invention provides at least one compound selected from Table 1; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0114] In one embodiment, the present invention provides at least one compound selected from Compound 1 to Compound 250 in Table 1; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0115] In one embodiment, the present invention provides a method for treating a benign or malignant disease of the breast or reproductive tract, comprising administering to a subject at least one compound selected from compound 1 to compound 250 of Table 1.

[0116] In one embodiment, the present invention provides a method for treating cancer, comprising administering to a subject at least one compound selected from Compound 1 to Compound 250 in Table 1.

[0117] In one embodiment, the present invention provides at least one compound selected from Compound 1 to Compound 250 in Table 1 for treating a benign or malignant disease of the breast or reproductive tract.

[0118] In one embodiment, the present invention relates to a pharmaceutical composition comprising at least one compound selected from Compound 1 to Compound 250 in Table 1, a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and at least one pharma- ceutically acceptable excipient.

[0119] In one embodiment, the present invention relates to a pharmaceutical composition for use in treating a benign or malignant disease of the breast or reproductive tract comprising at least one compound selected from compound 1 to compound 250 in Table 1, a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and at least one pharma- ceutically acceptable excipient.

[0120] Table 1: Novel compounds of the present invention [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15]

[0121] In one embodiment, the present invention relates to compounds of formula A; their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R'1 is an optionally substituted heterocycloalkyl, heteroaryl, and [ka] wherein one or more of the substituents on the optionally substituted heterocycloalkyl, heteroaryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl, and aryl groups, where one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups, where one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0122] In one embodiment, the present invention relates to compounds of formula B; their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] R1' is selected from: [ka] wherein R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl and aryl groups; wherein the one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; The solid circle represents an aromatic ring; X is independently N, O, S, [ka] Selected from; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms a double bond; or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0123] In one embodiment, the present invention relates to compounds of formula C; their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] where R1' is selected from: [ka] R2' is selected from: [ka] The solid circle represents an aromatic ring; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: X is independently N, O, S, [ka] Selected from; Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms a double bond; or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0124] In another embodiment, the present invention relates to compounds of formula (A); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof, wherein R'2 is selected from the group consisting of: [ka]

[0125] In another embodiment, the present invention relates to compounds of formula (A); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof, wherein R'1 is selected from optionally substituted heterocycloalkyl and heteroaryl, and is selected from the group consisting of: [ka] [ka]

[0126] In another embodiment, the present invention relates to compounds of formula (B); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof: [ka] where R1' is selected from: [ka] wherein R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl and aryl groups; wherein one or more of the substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. wherein one or more of the substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; The solid circle represents an aromatic ring; X is independently N, O, S, [ka] Selected from; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms a double bond; or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0127] In another embodiment, the present invention relates to compounds of formula (C); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] where R1' is selected from: [ka] R2' is selected from: [ka] The solid circle represents an aromatic ring; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: X is independently N, O, S, [ka] Selected from; Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms a double bond; or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0128] In another embodiment, the present invention relates to compounds of formula (D); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R3' and R4' taken together are an oxo bond; [ka] Form.

[0129] In another embodiment, the present invention provides a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [ka]

[0130] In another embodiment, the present invention relates to compounds of formula (E); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R3' and R4' taken together are an oxo bond; [ka] Form.

[0131] In another embodiment, the present invention relates to compounds of formula (F); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R3' and R4' taken together are an oxo bond; [ka] Form.

[0132] In another embodiment, the present invention relates to compounds of formula (G); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, taken together with the atom to which they are attached, are one or more groups selected from N, O and S; forms a 3 to 7 membered saturated, partially unsaturated or unsaturated ring, which may contain multiple heteroatoms, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; [ka] Form a bond.

[0133] In another embodiment, the present invention relates to a compound, a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof, selected from the group consisting of: [ka]

[0134] In another embodiment, the present invention relates to compounds of formula (H); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl is selected from one or more substituents is selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R3' and R4' taken together are an oxo bond; [ka] Form.

[0135] In another embodiment, the present invention relates to a compound selected from the group consisting of: [ka]

[0136] In another embodiment, the present invention relates to compounds of formula (W); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R3' and R4' taken together are an oxo bond; [ka] Form.

[0137] In another embodiment, the present invention relates to compounds of formula (J); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each of R"3 and R3', or R"4 and R4', taken together with the atoms to which they are attached, forms a double bond; or each of R"3 and R"4, or R3' and R4', taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0138] In another embodiment, the present invention relates to a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [ka]

[0139] In another embodiment, the present invention relates to compounds of formula (K); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; Each of R"3 and R"4, or R3' and R4' taken together, is an oxo bond. [ka] Form.

[0140] In another embodiment, the present invention relates to a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [ka] [ka]

[0141] In another embodiment, the present invention relates to compounds of formula (L); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and the ring is optionally substituted at any substitutable position with one or more R′5 radicals, where one or more R′5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or each R"3 and R"4, or R3' and R4' taken together are an oxo bond; [ka] Form.

[0142] In another embodiment, the present invention relates to a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka]

[0143] In another embodiment, the present invention relates to compounds of formula (M); their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates: [ka] Where: R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R"3 and R3', or R"4 and R4', or R"3 and R"4, or R3' and R4', together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring, which may contain one or more heteroatoms selected from N, O and S, and which ring is optionally substituted at any substitutable position with one or more R'5 radicals, where one or more R'5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, taken together with the atoms to which they are attached, form a double bond; or Each of R"3 and R"4, or R3' and R4' taken together, is an oxo bond. [ka] Form.

[0144] In another embodiment, the present invention relates to a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka]

[0145] In another embodiment, the present invention relates to compounds of formula (N); their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates: [ka] The solid circle represents an aromatic ring; X is independently N, O, S, [ka] Selected from; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0146] In another embodiment, the present invention relates to a compound of formula (O); a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] The solid circle represents an aromatic ring; X is independently N, O, S, [ka] Selected from; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0147] In another embodiment, the present invention relates to a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka]

[0148] In another embodiment, the present invention relates to a compound of formula (P); a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [ka] The dashed circle represents saturated, partially unsaturated, or fully unsaturated rings: Y is C, [ka] selected from N, O and S; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0149] In another embodiment, the present invention provides a compound: [ka] and their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates.

[0150] In another embodiment, the present invention relates to compounds of formula (Q); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof: [ka] The dashed circle represents saturated, partially unsaturated, or fully unsaturated rings: Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0151] In another embodiment, the present invention provides a compound selected from the group consisting of: [ka] It relates to the pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof.

[0152] In another embodiment, the present invention relates to compounds of formula (R); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof: [ka] The dashed circle represents saturated, partially unsaturated, or fully unsaturated rings: Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0153] In another embodiment, the present invention relates to compounds of formula (S); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof: [ka] Where; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [ka] selected from N, O and S; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0154] In another embodiment, the present invention provides a compound selected from the group consisting of: [ka] [ka] It relates to the pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof.

[0155] In another embodiment, the present invention relates to compounds of formula (T); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof: [ka] Where; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; Each R"4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0156] In another embodiment, the present invention relates to compounds of formula (T); pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof: [ka] Where; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; Each R''4 is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where one or more substitutions of the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0157] In one embodiment, the present invention provides a compound selected from the group consisting of: [ka] [ka] [ka] [ka] [ka] [ka] It relates to the pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates thereof.

[0158] In one embodiment is a pharmaceutical composition comprising a compound of formula (A); a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and a pharma- ceutically acceptable excipient.

[0159] In one embodiment is a pharmaceutical composition comprising a compound of formula (B); a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and a pharma- ceutically acceptable excipient.

[0160] In one embodiment is a pharmaceutical composition comprising a compound of formula (C); a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; and a pharma- ceutically acceptable excipient.

[0161] In one embodiment, a method for treating a benign or malignant disease of the breast or reproductive tract, preferably for treating breast cancer, comprising a compound of formula (A), an enantiomer, a diastereomer, a racemate, a pharma- ceutically acceptable salt or a solvate thereof: [ka] Here, R'1 is an optionally substituted heterocycloalkyl, heteroaryl, and [ka] wherein one or more of the substituents on the optionally substituted heterocycloalkyl, heteroaryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl, and aryl groups, where one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups, where one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

[0162] In one embodiment, a method for treating a benign or malignant disease of the breast or reproductive tract, preferably for treating breast cancer, comprising a compound of formula (B), an enantiomer, a diastereomer, a racemate, a pharma- ceutically acceptable salt or a solvate thereof: [ka] where R1' is selected from: [ka] wherein R'2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl and aryl groups; wherein the one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; The solid circle represents an aromatic ring; X is independently N, O, S, [ka] Selected from; wherein R″3, R″4, R3′, and R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atom to which they are attached, are selected from N, O, and S. or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms a double bond; or each R"3 and R"4, or R"4 and R"4, taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0163] In one embodiment, a method for treating a benign or malignant disease of the breast or reproductive tract, preferably for treating breast cancer, comprising a compound of formula (C); an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof: [ka] Wherein; R1' is selected from: [ka] R2' is selected from: [ka] The solid circle represents an aromatic ring; The dashed circle represents saturated, partially unsaturated, or fully unsaturated rings: X is independently N, O, S, [ka] Selected from; Y is C, [ka] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, the remaining atoms of the ring being carbon and each heteroatom being independently selected from nitrogen, oxygen, and sulfur, and ring A is optionally substituted with one or more R"6 radicals independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; wherein R″3, R″4, R3′, R4′ are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R″3 and R3′, or R″4 and R4′, or R″3 and R″4, or R3′ and R4′, together with the atoms to which they are attached, form a 3- to 7-membered saturated, partially unsaturated, or unsaturated ring, which may contain one or more heteroatoms selected from N, O, and S, and the ring may be optionally substituted at any substitutable position with one or more R′5 radicals, where the one or more R′5 radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each of R"3 and R3', or R"4 and R4', taken together with the atoms to which they are attached, forms a double bond; or each of R"3 and R"4, or R3' and R4', taken together with the atoms to which they are attached, forms an oxo bond; [ka] Form.

[0164] In another embodiment, the present invention relates to a pharmaceutical composition comprising at least one compound selected from the compounds of formula (Ia)-(I-bq); enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates thereof, and a pharma- ceutically acceptable excipient. The pharmaceutical composition of the present disclosure may be in any form known to those skilled in the art. The pharmaceutical composition of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, or via an implanted reservoir, preferably orally or by injection.

[0165] For example, in some embodiments, the pharmaceutical composition comprising the desired product is formulated for oral delivery, hi one embodiment, the pharmaceutical composition comprising the desired product is selected from the group consisting of a concentrate, a dry powder, a liquid, a capsule, a pellet, and a tablet.

[0166] For example, in some embodiments, the pharmaceutical composition comprising the desired product is for parenteral administration, hi one embodiment, the pharmaceutical composition comprising the desired product is selected from the group consisting of intravenous injection, intramuscular injection, subcutaneous injection, powder for injection solution, powder for injection suspension, liposomes, oil injection, and sustained release particles.

[0167] In one embodiment, the compound for the pharmaceutical composition is a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, Formula G, Formula H, Formula W, Formula J, Formula K, Formula L, Formula M, Formula N, Formula O, Formula P, Formula Q, Formula R, Formula S, Formula T, Formula U; a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0168] In one embodiment, the present invention provides a pharmaceutical composition comprising a pharma- ceutically acceptable excipient selected from a carrier, a binder, a diluent, a filler, a preservative, a disintegrant, a flow regulator, a plasticizer, a wetting agent, a dispersant, an emulsifier, a solvent, and an antioxidant.

[0169] In another embodiment, the present invention provides the use of a compound of the present invention in the preparation of a pharmaceutical formulation as described herein for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably for the treatment of breast cancer.In another embodiment, the present invention provides a compound for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably for the treatment of breast cancer.

[0170] In another embodiment, the compounds of the present invention find use in the treatment of estrogen-dependent indications such as breast cancer and gynecological disorders such as endometriosis.

[0171] In another embodiment, the pharmaceutical composition of the present invention comprises at least one compound selected from compounds (Ia)-(I-bq) and a pharma- ceutical acceptable excipient in the treatment of estrogen-dependent indications, such as breast cancer and gynecological diseases, such as endometriosis.

[0172] In another embodiment, the present invention provides a method for treating a benign or malignant disease of the breast or reproductive tract, preferably a method for treating breast cancer, comprising the administration of at least one compound selected from Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, Formula G, Formula H, Formula W, Formula J, Formula K, Formula L, Formula M, Formula N, Formula O, Formula P, Formula Q, Formula R, Formula S, Formula T, Formula U; or a pharma-ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0173] In another embodiment, the present invention provides a method of treating a benign or malignant disease of the breast or reproductive tract, preferably a method of treating breast cancer, comprising administering a pharmaceutical composition comprising a compound of at least one formula selected from Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, Formula G, Formula H, Formula W, Formula J, Formula K, Formula L, Formula M, Formula N, Formula O, Formula P, Formula Q, Formula R, Formula S, Formula T, Formula U; or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof.

[0174] In another embodiment, the present invention provides a method for treating a benign or malignant disease of the breast or reproductive tract, preferably breast cancer, comprising administering at least one compound selected from compounds (Ia)-(I-bq).

[0175] In another embodiment, the present invention provides a method for treating a benign or malignant disease of the breast or reproductive tract, preferably for treating breast cancer, comprising administration of a pharmaceutical composition comprising at least one compound selected from compounds (Ia)-(I-bq) and a pharmaceutically acceptable excipient.

[0176] In another embodiment, the present invention provides a pharmaceutical composition for treating a benign or malignant disease of the breast or reproductive tract, comprising at least one compound selected from compounds (Ia)-(I-bq) and a pharmaceutically acceptable excipient.

[0177] In another embodiment, the present invention provides at least one compound selected from compounds (Ia)-(I-bq) for treating a benign or malignant disease of the breast or reproductive tract.

[0178] In other embodiments, the present disclosure also relates to novel novel compounds, as well as their stereochemically isomeric forms, hydrates, solvates or pharma- ceutically acceptable salts; either alone or in combination with at least one additional therapeutic agent, for the treatment of the disease and / or condition that the original agent is intended to treat. The combination with the additional therapeutic agent may take the form of a combination of the novel compounds with any known therapeutic agent.

[0179] The following examples are given for the purpose of illustrating the present invention and should not be construed as limiting the scope of the present invention.

[0180] Working Example List of Abbreviations PCC - Pyridinium Chlorochromate DMP - Dess-Martin Periodont DCM - dichloromethane DIPEA - Diisopropylethylamine NaBH(OAC)3- Sodium triacetoxyborohydride BnBr - benzyl bromide Mel - Methyl iodide

[0181] Example-1: Preparation of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (0.9 g) in dichloromethane (10 mL) was added pyridinium chlorochromate (0.323 g) under nitrogen atmosphere and the resulting suspension was stirred at room temperature for 10 minutes. After completion of the reaction by TLC, the reaction mixture was diluted with water (10 mL). The organic compounds were extracted with dichloromethane (3x200 mL) and washed with water (2x200 mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude product was purified by preparative HPLC using trifluoroacetic acid as a modifier to give 0.061 g of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one as a white solid.

[0182] LCMS purity: 98.74% 1H-NMR(DMSO-d6):δ9.00(br s,1H),7.05-7.03(d,1H),6.50-6.51(dd,1H),6.43-6.42(d,1H),2.85-2.61(m,6H),2.41-2.23(m,5H),2. 11-2.01(m,1H),1.93-1.81(m,4H),1.69-1.51(m,6H),1.36-1.14(m,15H),0.89-0.92(m,1H),0.80(s,3H).

[0183] Example-2: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-4-(pyrrolidin-1-yl)piperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-4-(pyrrolidin-1-yl)piperidine-1-carboxylate (0.5 g) in dichloromethane (10 mL) was added Dess-Martin periodinane (DMP) (0.323 g) at a temperature of 0° C. under a nitrogen atmosphere. The resulting suspension was stirred at room temperature for 4 hours. After TLC showed the reaction to be complete, the reaction mixture was diluted with water (10 mL). The organic compound was extracted with dichloromethane (3×50 mL), washed with water (2×200 mL) and dried over anhydrous sodium sulfate. The dried organic layer was concentrated under reduced pressure to give the crude material. The crude material was purified by preparative HPLC using trifluoroacetic acid as a modifier to give 0.156 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-4-(pyrrolidin-1-yl)piperidine-1-carboxylate as a white solid.

[0184] LCMS purity: 95.67% 1 H-NMR(DMSO-d6): δ7.29-7.26(d,1H),6.83-6.81(d,1H),6.78(s.1H),4.22-4 .08(m,2H),3.61-3.41(m,2H),3.34-3.32(t,1H),3.07-3.03(m,3H),2.93-2.8 1(m,3H),2.74-2.63(m,3H),2.40-2.29(m,3H),2.07-2.02(m,6H),1.93-1.83( m,7H),1.75-1.53(m,9H),1.43-1.13(m,15H),0.89-0.87(m,1H),0.80(s,3H).

[0185] Example-3: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylic acid (0.5 g) in dichloromethane (10 mL) was added Dess-Martin periodinane (DMP) (0.323 g) at a temperature of 0° C. under a nitrogen atmosphere. The resulting suspension was stirred at room temperature for 6 hours. After TLC showed the reaction to be complete, the reaction mixture was diluted with water (10 mL). The organic compound was extracted with dichloromethane (3x50mL), washed with water (2x200mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material, which was purified by preparative HPLC using trifluoroacetic acid as modifier to give 0.13g of 7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate as a white sticky solid.

[0186] LCMS purity: 99.70% 1H-NMR(DMSO-d6): δ7.26-7.24(d,1H),6.81-6.79(d,1H),6.75(s.1H),3.99-4.09(m,2H),3.55-3.58(m,4H),2.95-2.61(m,8H),2 .45-2.28(m,10H),2.10-2.01(m,1H),1.93-1.81(m,6H),1.74-1.52(m,6H),1.33-1.14(m,17H),0.87-0.89(m,1H),0.80(s,3H).

[0187] Example-4: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate [ka] To a stirred solution of oxalyl chloride (0.310 mL) in dichloromethane (113 mL) was added dropwise dimethylsulfoxide (0.625 mL) cooled to −75° C. under nitrogen atmosphere. Then, (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4′-bipiperidine]-1′-carboxylic acid (2.5 g) in dichloromethane (25 mL) was added dropwise to the above mixture over 30 minutes. The temperature of the reaction mixture was maintained at -75°C for 2.5 hours and N,N'-diisopropylamine (4.12 mL) was added. The resulting reaction mixture was kept stirring at room temperature for 30 minutes. After TLC showed the reaction was complete, the mixture was diluted with water (25 mL). The reaction mass was extracted with dichloromethane (3X20 mL), washed with water (2X10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude material was purified by flash chromatography to give 0.75 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate as a white sticky solid.

[0188] LCMS purity: 96.79% 1 H-NMR(DMSO-d6): δ7.28-7.26(d,1H),6.84-6.82(d,1H),6.80(s,1H),4.15-4 .01(m,2H),2.96-2.99(m,1H),2.90-2.69(m,7H),2.67-2.61(m,1H),2.71-2.3 5(m,9H),2.10-2.05(m,1H),1.94-1.85(m,4H),1.76-1.56(m,8H),1.54-1.47( m,4H),1.38-1.33(m,9H),1.25-1.23(m,10H),0.92-0.89(m,1H),0.83(s,3H).

[0189] Example-5: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1-methylpyrrolidin-3-yl)carbonate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.5 g) in dichloromethane (6 mL) was added triphosgene (0.122 g) and DIPEA (0.160 g) at a temperature of 0 °C under nitrogen atmosphere. The resulting reaction mixture was stirred at 0 °C for 15 minutes. Then, 1-methylpyrrolidin-3-ol (0.125 g) was added to the above reaction mixture and stirring was continued at room temperature for 2 hours. After confirming the completion of the reaction by TLC, the mixture was diluted with water (10 mL). The organic compounds were extracted with dichloromethane (3×20 mL) and then washed with water (2×10 mL). The collected organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude material was purified by preparative HPLC using ammonium bicarbonate as modifier to give 0.07 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1-methylpyrrolidin-3-yl)carbonate as a white sticky solid.

[0190] LCMS purity: 99.28% 1H-NMR (DMSO-d6): δ7.33-7.31(d,1H),6.97-6.94(d,1H),6.93(s,1H),2. 96-2.80(m,3H),2.76-2.69(m,4H),2.64-2.59(m.2H),2.46-2.34(m,8H), 2.28-2.18(m,5H),2.15-2.05(m,1H),1.94-1.77(m,6H),1.73-1.54(m,6 H),1.43-1.34(m,6H),1.29-1.17(m,6H).0.94-0.89(m,1H),0.84(s,3H).

[0191] Example-6: Preparation of (7R,8R,9S,138,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate

[0192] Step-1: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (1 g) in acetonitrile (10 mL) was added cesium carbonate (1.62 g) and 4-nitrophenyl chloroformate (0.5 g) at room temperature, and the reaction mixture was stirred at the same temperature for 15 minutes. After checking the completion of the reaction by TLC, the reaction solution was diluted with water (15 mL) and extracted with ethyl acetate (2x50 mL). The combined organic layers were dried over anhydrous sodium sulfate and the organic matter was concentrated under reduced pressure to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (1.2 g crude), which was used in the next step without further purification.

[0193] Step-2: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate [ka] To a pre-stirred suspension of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (1 g) and potassium carbonate (0.62 g) in dimethylformamide (12 mL) was added tromethamine (0.3 g) at room temperature under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for an additional 2 h. After completion of the reaction by TLC, the mixture was diluted with water (20 mL), extracted with ethyl acetate (3x50 mL), washed with water (2x20 mL), and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude product was purified by preparative HPLC using trifluoroacetic acid as a modifier to give 0.030 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl (1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate as an off-white semi-solid.

[0194] LCMS purity: 99.53% 1 H-NMR (DMSO-d6): δ7.27(d,1H),6.84(d,1H),6.81(s.1H),6.70(brs,1H),4.54-4.51(t,3H),3.57(d,6H),2.88-2.71(m,5H),2. 64-2.62(m,1H),2.44-2.37(m,4H),2.12-2.08(m,1H),1.92-1.56(m,11H),1.40-1.14(m,15H),0.91-0.88(m.1H),0.84(s,3H).

[0195] Example-7: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 6-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylate [ka] To a pre-stirred suspension of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (1 g, prepared in Example-6, step-1) and potassium carbonate (1.8 g) in acetonitrile (40 mL), 2-methyl-2,6-diazaspiro[3.3]heptane bis(trifluoroacetate) (0.66 g) was added at a temperature of 0° C. under a nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 16 hours. After confirming the completion of the reaction by TLC, the mixture was diluted with water (20 mL). The organic compound was extracted with ethyl acetate (3X50mL), washed with water (2X20mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude material was purified by preparative HPLC using trifluoroacetic acid as modifier to give 0.374g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 6-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylic acid monotrifluoroacetate as a white semi-solid.

[0196] LCMS purity: 98.71% 1H-NMR (DMSO-d6): δ9.51(brs,1H),7.28(d,1H),6.82(d,1H),6.78(s,1H),4.40-4.36(m,2H),4.32-4.27(m,2H),4.15-4.11(m,4H) ,2.96-2.71(m,9H),2.44-2.39(m,4H),2.14-2.05(m,1H),1.92-1.53(m,11H),1.44-1.15(m,15H),0.93-0.88(m,1H),0.83(s,3H).

[0197] Example-8: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(dimethylamino)piperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.5 g) in dichloromethane (10 mL) was added DIPEA (0.21 mL) and triphosgene (0.122 g) at a temperature of 0° C. under nitrogen atmosphere, and the resulting mixture was stirred at the same temperature for 10 minutes. After 10 minutes, N,N-dimethylpiperidin-4-amine (0.158 g) was added into the reaction mixture at a temperature of 0° C., and the reaction mixture was stirred at room temperature for 1.5 hours. After TLC showed the reaction was complete, the reaction mass was diluted with water (20 mL) and extracted with dichloromethane (3x20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by flash chromatography to give 0.2 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(dimethylamino)piperidine s-1-carboxylate as an off-white solid.

[0198] LCMS purity: 95.60% 1 H-NMR(DMSO-d6): δ7.28-7.26(d,1H),6.86-6.83(d,1H),6.81(s,1H),4.1 2-4.01(m.2H),3.01-2.89(m,1H),2.90-2.61(m,7H),2.43-2.33(m,11H), 2.14-2.05(m,1H),1.92-1.84(m,6H),1.79-1.68(m,3H),1.65-1.54(m,3H ),1.39-1.33(m,8H),1.23-1.18(m,10H),0.94-0.91(m.1H),0.84(s,3H).

[0199] Example-9: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate

[0200] Step-1: Preparation of tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate [ka] To a stirred solution of N-bocpiperidin-4-one (1 g) and 2-aminoethanol (0.31 g) in dichloromethane (20 mL) was added catalytic amount of glacial acetic acid (0.1 mL) at 0° C. under nitrogen atmosphere and the resulting reaction mixture was stirred at 0° C. for 1 hour. Sodium triacetoxyborohydride (2.66 g) was then added in portions to the reaction mixture and the resulting reaction mixture was stirred at room temperature under nitrogen atmosphere for 4 hours. After TLC showed the reaction was complete, the reaction mass was diluted with saturated aqueous sodium bicarbonate (50 mL) and extracted with dichloromethane (3×40 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by flash chromatography to give 0.75 g of tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate as an off-white semi-solid.

[0201] Step-2: Preparation of 2-(piperidin-4-ylamino)ethan-1-ol [ka] To a stirred solution of tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate (0.75 g) in dioxane (15 mL) was added 4N hydrochloric acid in dioxane (8 mL) at a temperature of 0° C. under nitrogen atmosphere, and the resulting reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction was confirmed by TLC, the reaction mixture was concentrated under reduced pressure to give the crude material. The crude material was further washed with diethyl ether (10 mL0) to give 2-(piperidin-4-ylamino)ethan-1-ol (0.7 g) as an off-white solid.

[0202] Step-3: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.6 g) in dichloromethane (12 mL), DIPEA (0.43 mL) and triphosgene (0.15 g) were added at a temperature of 0° C., and the reaction mixture was stirred at the same temperature for 10 minutes. After 10 minutes, 2-(piperidin-4-ylamino)ethan-1-ol dihydrochloride (0.32 g) was added to the reaction mixture at a temperature of 0° C., and the reaction mixture was stirred at room temperature for 1.5 hours. After TLC showed the reaction was complete, the reaction mass was diluted with water (20 mL) and extracted with dichloromethane (3x25 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by flash chromatography to give 0.030 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate as an off-white semi-solid.

[0203] LCMS purity: 95.22% 1 H-NMR(DMSO-d6): δ7.27(d,1H),6.85-6.81(m,2H),4.62(brs,1H),4.-01-3.92(m,2H),3.49-3.48(m,2H),3.09-3.06(m,1H),2.96-2.71( m,9H),2.64-2.61(m,2H),2.44-2.39(m,4H),2.14-2.06(m,1H),1.94-1.54(m,13H),1.39-1.24(m,17H),0.94-0.89(m.1H),0.84(s,3H).

[0204] Example-10: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 3-oxa-8-azabicyclo[3.2.1]octane-8-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.5 g) in dichloromethane (10 mL) was added DIPEA (0.288 mL) and triphosgene (0.122 g) at a temperature of 0° C., and the reaction mixture was stirred at the same temperature for 10 minutes. After 10 minutes, 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (0.185 g) was added into the reaction mixture at a temperature of 0° C., and the reaction mixture was stirred at room temperature for 1.5 hours. After TLC showed the reaction was complete, the reaction mass was diluted with water (20 mL) and extracted with dichloromethane (3x20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by preparative HPLC using ammonium bicarbonate as modifier to give 0.030 g of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 3-oxa-8-azabicyclo[3.2.1]octane-8-carboxylate as a white semi-solid.

[0205] LCMS purity: 92.99% 1H-NMR(DMSO-d6): δ7.30-7.28(d,1H),6.89-6.87(d.1H),6.861(s,1H),4.25-4 .09(m,2H),3.66-3.61(m,4H),2.91-2.80(m,3H),2.76-2.69(m,2H),2.64-2.6 1(m,1H),2.44-2.33(m,4H),2.12-2.08(m,1H),1.94-1.85(m,8H),1.80-1.66( m,3H),1.62-1.54(m,3H),1.39-1.24(m,16H),0.94-0.87(m,1H),0.84(s,3H).

[0206] Example-11: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol (0.300 g) in dichloromethane (10 mL) was added DIPEA (0.092 g) and triphosgene (0.071 g) at a temperature of 0° C. under nitrogen atmosphere and the resulting mixture was stirred at a temperature of 0° C. for 10 minutes. Thereafter, 1,4′-bipiperidine (0.121 g) was added to the above mixture and the reaction mass was stirred at room temperature for 4 hours. After TLC showed the reaction was complete, the mixture was diluted with water (10 mL), extracted with dichloromethane (3x40 mL), washed with water (2x20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude material. The crude material was purified by pre-HPLC using trifluoroacetic acid as a modifier to obtain 0.118 g of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14.15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylic acid monotrifluoroacetate as a white solid.

[0207] LCMS purity: 98.86% 1 H-NMR (DMSO-d6): δ9.08(brs,1H),7.28(d,1H),6.84(d,1H),6.79(s,1H),4.24-4.16(m,2H),3.43-3.29(m,5H),3.26(s,3H),2. 98-2.61(m,10H),2.39-2.33(m,3H),2.07-1.84(m,8H),1.72-1.52(m,9H),1.39-1.15(m,19H),0.90-0.85(m,1H),0.72(s,3H).

[0208] Example-12: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5M5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol (0.400 g) in dichloromethane (10 mL) was added DIPEA (0.092 g) and triphosgene (0.094 g) at 0° C. and the resulting reaction mixture was stirred at 0° C. for 10 minutes. Thereafter, 4-(piperidin-4-yl)morpholine (0.164 g) was added and the reaction mass was stirred at room temperature for 4 hours. After completion of the reaction by TLC, the mixture was diluted with water (10 mL) and then extracted with dichloromethane (3×40 mL). The collected organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude material. The crude material was purified by preparative HPLC using trifluoroacetic acid as a modifier to obtain 0.113 g of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylic acid mono-trifluoroacetate as a white solid.

[0209] LCMS purity: 97.76% 1H-NMR(DMSO-d6): δ9.72(brs,1H),7.28(d,1H),6.85-6.82(dd,1H),6.78 (d,1H),4.23-3.90(m,4H),3.70-3.33(m,3H),3.28(t,1H),3.23(s,3H),3 .14-2.87(m,3H),2.85-2.63(m,8H),2.24-2.27(m,3H),2.13-1.86(m,6H ),1.72-1.52(m,7H),1.42-1.14(m,19H),0.90-0.87(m,1H),0.72(s,3H).

[0210] Example-13: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(pyrrolidin-1-yl)piperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol (0.4 g) in dichloromethane (10 mL) was added DIPEA (0.092 g) and triphosgene (0.094 g) at 0° C., and the resulting reaction mixture was stirred at 0° C. for 10 min. Then, 4-(pyrrolidin-1-yl)piperidine (0.164 g) was added to the above solution, and stirring was continued at room temperature for 4 h. After confirming the completion of the reaction by TLC, the mixture was diluted with water (10 mL). The reaction was extracted with dichloromethane (3×40 mL) and then washed with water (2×100 mL). The collected organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude material was purified by preparative HPLC using trifluoroacetic acid as a modifier to give 0.155 g of (7R,8R,9S,138,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(pyrrolidin-1-yl)piperidine-1-carboxylic acid monotrifluoroacetate as a white semi-solid.

[0211] LCMS purity: 97.74% 1 H-NMR (DMSO-d6): δ9.56(brs,1H),7.27(d.1H),6.82(d.1H),6.76(s.1H),4.19-4.09(m,2H),3.51-3.27(m,3H),3.24(s,3H),3.08-3.01( m,3H),2.93-2.70(m,6H),2.29-2.09(m,4H),2.01-1.83(m,10H),1.69-1.43(m,7H),1.37-1.14(m,19H),0.85-0.87(m,1H),0.72(s,3H).

[0212] Example-14: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol

[0213] Step-1: Preparation of (7R,8R,9S,13S,14S,17S)-3-(benzyloxy)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (30 g) in acetone (300 mL) was added potassium carbonate (20.49 g) and benzyl bromide (15.23 g) at 0° C. The resulting solution was stirred at 60° C. for 16 hours. After completion of the reaction by TLC, the mixture was diluted with ethyl acetate (20 mL). The organic compounds were extracted with ethyl acetate (3X70 mL), washed with water (2x200 mL), and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude material was purified by flash chromatography (23% ethyl acetate:n-heptane) to give 17 g of (7R,8R,9S,13S,14S,17S)-3-(benzyloxy)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene as a colorless liquid.

[0214] Step-2: Preparation of (7R,8R,9S,13S,14S,17S)-3-(benzyloxy)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-3-(benzyloxy)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene (8 g) in N,N-dimethylformamide (20 mL) was added sodium hydride (0.827 g) and the resulting reaction mixture was stirred for 30 minutes. Thereafter, methyl iodide (8.09 g) was added to the above mixture and the reaction mass was stirred at room temperature for 16 hours. After confirming the completion of the reaction by TLC, the reaction mixture was quenched with cold water (300 mL). The organic compound was extracted with ethyl acetate (3x250mL), washed with water (3x500mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material, which was purified by flash chromatography (28% ethyl acetate in n-heptane) to give 4.5g of (7R,8R,9S,135,14S,17S)-3-(benzyloxy)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene as a colorless oil.

[0215] Step-3: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol (4.5 g) in methanol (50 mL) was added 10% Pd / C (1.5 g) and ammonium formate (3.1 g). The resulting mixture was stirred at room temperature for 5 h. After TLC showed the reaction was complete, the reaction mixture was filtered through a pad of Celite and washed thoroughly with methanol. The resulting filtrate was concentrated under reduced pressure to give the crude material. The crude was purified by flash chromatography (42% ethyl acetate in n-heptane, 78%, 1.8 g). The crude compound was purified by preparative HPLC (TFA method) to give 0.086 g of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol as a white solid.

[0216] LCMS purity: 98% (Peak-1, RT 6.16 min: 52.45%, Peak-2, RT 6.24 min: 45.83%). 1H-NMR (DMSO-d6): δ7.03(d,1H),6.49(dd,1H),6.40(d,1H),3.28-3.26(m,2H),3.25(s,3H),2.88-2.71(m,4H),2.64-2.58(m,2H) ,2.42-2.16(m,4H),1.93-1.83(m,4H),1.64-1.56(m,3H),1.49-1.44(m,2H),1.33-1.13(m,17H),0.90-0.81(m,1H),0.67(s,3H).

[0217] Example-15: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate

[0218] Step-1: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol (0.3 g) in acetonitrile (3 mL) was added cesium carbonate (0.47 g) and 4-nitrophenyl chloroformate (0.15 g) at room temperature, and the reaction mixture was stirred at the same temperature for 15 min. After completion of the reaction by TLC, the reaction mass was diluted with water (15 mL) and extracted with ethyl acetate (2x25 mL). The combined organic layers were dried over anhydrous sodium sulfate and the organic layer was concentrated under reduced pressure to give (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.38 g crude), which was used in the next step without further purification.

[0219] Step-2: Preparation of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.380 g) in DMF (4 mL) was added 2-amino-2-(hydroxymethyl)propane-1,3-diol (0.175 g). The resulting mixture was stirred at room temperature for 2 hours. After TLC showed the reaction was complete, the mixture was diluted with water (2 mL). The organic compound was extracted with ethyl acetate (3X5 mL), washed with water (2X20 mL), and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude product was purified by preparative HPLC using trifluoroacetic acid as a buffer to obtain 0.040 g of 7R,8R,9S,13S,14S,17S)-17-methoxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(1,3-dihydroxy-2-hydroxymethyl)propan-2-yl)carbamate as a white solid.

[0220] LCMS purity: 99.71% 1H-NMR (DMSO-d6): δ7.25(d.1H),6.82(dd,1H),6.78(d,1H),6.68(brs.1H),4.53-4.50(t,3H),3.56(d,6H),3.30-3.28(m,2H),3.26(s ,3H),2.88-2.61(m,6H),2.43-2.23(m,3H),2.06-1.88(m,4H),1.72-1.52(m,5H),1.39-1.15(m,17H),0.91-0.89(m,1H),0.72(s,3H).

[0221] Example-16: Preparation of ((7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)boronic acid

[0222] Step-1: Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-3-(((trifluoromethyl)sulfonyl)oxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (8 g) in dichloromethane (80 mL), pyridine (18 mL) and trifluoromethanesulfonic anhydride (5.67 g) were added at a temperature of 0° C. and the resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the mixture was diluted with water and extracted with dichloromethane. The organics were collected and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude material was purified by flash chromatography (10% ethyl acetate in n-heptane) to give (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-3-(((trifluoromethyl)sulfonyl)oxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (6.88 g, 71.66%) as a pale yellow semi-solid.

[0223] 1 H-NMR(400MHz,DMSO-d6):δ7.46(d,J=8.40Hz,1H),7.17-7.19(m,2H),4.63(t,J=8.40Hz,1H),2.91-2.79(m,2H),2.55-2.57(m,2H),2.33-2 .24(m,3H),2.12-2.11(m,1H),2.00(s,2H),1.74-1.73(m,3H),1.65-1 .68(m,1H),1.57-1.48(m,4H),1.36-1.22(m,19H),0.85-0.79(m,8H).

[0224] Step-2: Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-3-(((trifluoromethyl)sulfonyl)oxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (6.8 g) in 1,4-dioxane (60 mL) under a nitrogen atmosphere was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (3.4 g) and potassium acetate (1.3 g). The reaction mixture was purged with nitrogen gas for 10 minutes and palladium(II) acetate (0.398 g) was added followed by tricyclohexylphosphine (1.2 g). After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by CombiFlash chromatography to give (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (5.5 g, 83%) as a colorless semi-solid.

[0225] 1H-NMR(400MHz,DMSO-d6):δ7.58(d,J=8.00Hz,1H),7.54(s,1H),7.30(d,J=8.00Hz,1H),4.70(t,J=8.80Hz,1 H),2.93-2.80(m,2H),2.58(t,J=7.20Hz,2H),2.50(t,J=7.60Hz,2H),2.44-2.34(m,2H),2.26-2.16(m,3H),2 .16(s,3H),1.92-1.84(m,3H),1.77-1.75(m,1H),1.69-1.64(m,2H),1.58-1.60(m,1H),1.49-1.41(m,3H),1 .39-1.30(m,15H),1.27-1.17(m,10H),1.19-1.17(m.2H),0.99-0.97(m,1H),0.88-0.06(m,1H),0.80(s,3H).

[0226] Step-3: Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ylacetic acid (4-(2-(trifluoromethyl)morpholino)phenyl)carbamate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (5.5 g) in dichloromethane (20 mL) was added m-chloroperbenzoic acid (1.27 g) at a temperature of 0° C. and the mixture was stirred at room temperature for 2.5 hours. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated sodium carbonate solution and extracted with dichloromethane (3×200 mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude material was purified by washing with n-pentane to give (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (4.0 g, 71%) as a sticky solid.

[0227] LCMS purity: 98.74% (m / z: 759.52, [M+1] + , 3.29 min (4 min run), 214 nm).

[0228] Step-4: Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (0.5 g) in methanol (7.5 mL) was added 1 M lithium hydroxide (3 mL) at 0° C. and the resulting solution was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated NH4Cl solution (2 mL). The organic compounds were extracted with dichloromethane (3x20mL) and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol (5, 0.380g, crude) as a semi-solid, which was used in the next step without purification.

[0229] LCMS purity: 68.72% (m / z: 638.34 [M+1]+, 4.36 min (6 min run), 214 nm).

[0230] Step-5: Preparation of (7R,8R,9S,13S,14S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol (0.380 g) in dichloromethane (8 mL), Dess-Martin periodinane (0.270 g) was added and the resulting mixture was stirred at room temperature for 8 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water (5 mL). The reaction mass was extracted with dichloromethane (3x50 mL) and washed with water (2x200 mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain (7R,8R,9S,13S,14S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.390 g, crude) as a yellowish sticky liquid which was used in next step without purification.

[0231] LCMS purity: 98.74% (m / z: 715.33 [M+1]+, 2.96 min (4 min run), 214 nm).

[0232] Step-6: Preparation of ((7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)boronic acid [ka] To a stirred solution of (7R,8R,9S,13S,14S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.390 g) in methanol (4.5 mL) was added 1 M lithium hydroxide (2.5 mL) at 0° C. and the resulting solution was stirred at room temperature for 24 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated aqueous ammonium chloride solution (3 mL). The organic compound was extracted with DCM (3x50mL) and washed with water (2x100mL), the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC using trifluoroacetic acid buffer to give ((7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)boronic acid (0.03g, 11%) (0.38g, 11%) as a white solid.

[0233] LCMS: 99.24% (m / z:633.40, [M+1]+, 6.82 min (10 min run), 214 nm). 1 H-NMR(400MHz,DMSO-d6-D2O):δ7.49(d,J=7.60Hz,1H),7.45(s,1H),7.23 (d,J=7.60Hz,1H),2.89-2.79(m,3H),2.76-2.60(m,5H),2.45-2.28(m,4H) ,2.10-2.03(m,1H),1.91-1.83(m,4H),1.77-1.62(m,3H),1.60-1.53(m,3H ),1.37-1.32(m,6H),1.21-111.00(m,8H),0.88-0.91(m.1H),0.81(s,3H).

[0234] Example-17: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-(trifluoromethyl)morpholine-4-carboxylate (Compound 108)

[0235] Step-1: Preparation of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one [ka] Oxalyl dichloride (0.8 g) was stirred in dry dichloromethane (48 mL) at -70°C under nitrogen. A solution of dimethylsulfoxide (1.65 mL) in dry dichloromethane (50 mL) was added dropwise to the above solution over 10-15 minutes while maintaining the internal temperature below -60°C. After stirring the mixture for 5 minutes, a solution of fulvestrant (5 g) in dry dichloromethane (50 mL) was added dropwise over 15 minutes while maintaining the same temperature. After stirring the mixture at -70°C for 2 hours, N,N'-diisopropylamine (8.3 mL) was added over 5 minutes and the mixture was stirred at -70°C for an additional 30 minutes and then allowed to warm to room temperature. The reaction was monitored by TLC (70% ethyl acetate in n-heptane). After completion of the reaction, water (80 mL) and dichloromethane (80 mL) were added successively to the reaction mass and the mixture was stirred for 25 minutes followed by further addition of water (160 mL) and dichloromethane (160 mL). The phases were separated and the organic phase was washed with water (500 mL) followed by drying over anhydrous sodium sulfate for 16 hours and evaporation to give (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (4.5 g, 91.8%) as an off-white solid.

[0236] LCMS: 93.93%, (m / z:605.25)[M+1]+, 2.52 min (4 min run), 214 nm). 1 H NMR(400MHz,DMSO-d6):δ9.01(s,1H),7.05(d,J=8.40Hz,1H),6.51(d,J=8.80Hz,1H),6.44(s,1H),2.86-2.61(m,8H),2.43 -2.25(m,6H),2.11-1.98(m,1H),1.92-1.81(m,3H),1.68-1.35(m,6H),1.33-1.24(m,12H),0.95-0.96(m,2H),0.82(s,3H).

[0237] Step-2: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-2-(trifluoromethyl)morpholine-4-carboxylate [ka] To the stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.5 g) was dissolved in dichloromethane (10 mL), DIPEA (0.21 mL) and triphosgene (0.122 g) were added at 0° C., and the resulting mixture was stirred at the same temperature for 10 minutes. After 10 minutes, 2-(trifluoromethyl)morpholine hydrochloride (0.237 g) was added to the reaction mixture at 0° C., and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mass was diluted with water (20 mL) and extracted with dichloromethane (3x20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by preparative HPLC using trifluoroacetic acid as a buffer to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-(trifluoromethyl)morpholine-4-carboxylate (0.078 g, 11%) as a pale yellow solid.

[0238] LCMS: 97.36%, (m / z:786.35)[M+1]+, 7.27 min (10 min run), 214 nm). 1H-NMR(400MHz,DMSO-d6-D2O):δ7.28(d,J=8.80Hz,1H),6.86(d,J=8.40Hz,1H),6.83(s,1H), 4.30-4.07(m,2H),3.97-3.99(m,2H),3.67-3.65(m,1H),3.25-3.10(m,2H),2.87-2.79(m,2H ),2.75-2.69(m,2H),2.67-2.61(m,4H),2.44-2.27(m,4H),2.15-2.02(m,1H),1.93-1.82(m, 4H),1.76-1.53(m,5H),1.41-1.29(m,6H),1.29-1.10(m,9H),0.90-0.88(m,1H),0.81(s,3H).

[0239] Example-18: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(2-(dimethylamino)ethyl)carbamate (Compound 115) [ka] To a stirred solution of (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (1 g, as prepared in Example-17, step-1) in dichloromethane (16 mL), DIPEA (0.42 mL) and (0.24 g) were added at 0° C. and the resulting reaction mixture was stirred at the same temperature for 10 minutes. After 10 minutes, N,N'-dimethylethane-1,2-diamine (0.21 g) was added to the above reaction mixture at 0° C. and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mass was diluted with water (25 mL) and extracted with dichloromethane (2x25 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 0.8 g of crude material.

[0240] LCMS: 42.55%, (m / z:719.15)[M+1]+, 3.24 min (4 min run), 214 nm).

[0241] Example-19: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-(4-methylpiperazin-1-yl)acetate (Compound 250) [ka] To a stirred solution of 2-(4-methylpiperazin-1-yl)acetic acid (0.16 g) in dichloromethane (8 mL), 4-dimethylaminopyridine (0.02 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.20 g) were added at 0° C. and the resulting reaction mixture was stirred for 10 minutes at 0° C. Thereafter, (7R,8R,9S,13S,14S)-3-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (0.5 g, as prepared in Example-17, step-1) was added and the reaction mass was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mass was diluted with ice water (30 mL) and extracted with dichloromethane (3x30 mL). The combined organic layers were washed with water (2x40 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 0.316 g of crude material. The crude material was purified by reverse phase HPLC to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-(4-methylpiperazin-1-yl)acetate (0.073 g, 11.8%) as a white solid.

[0242] LCMS: 81.91% (m / z: 744.40, [M+1]+, 2.33 min, 214 nm).

[0243] Example-20: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate [ka] To a stirred solution of 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (0.15 g) in acetonitrile (10 mL), potassium carbonate (0.21 g) was added and the resulting reaction mixture was stirred at room temperature for 2 hours. Thereafter, (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.4 g, as prepared in Example-6, step-1) was added to the above stirred solution and the reaction mass was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction was diluted with ice water (30 mL) and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with water (2x40 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 0.5 g of crude material. The crude material was purified by preparative HPLC to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate (0.081 g, 20%) as a white solid.

[0244] LCMS: 96.79% (m / z: 751.50, [M+1]+, 7.24 min, 214 nm). 1 HNMR(400MHz,DMSO-d6):δ8.49(d,J=4.4Hz,1H),7.82(d,J=7.6Hz,1H),7.36-7.31(m ,2H),6.94(d,J=8.8Hz,1H),6.91(s,1H),4.88(d,J=28.80Hz,2H),4.71(d,J=27.6F,2 H),2.94-2.80(m,3H),2.76-2.61(m,4H),2.44-2.30(m,5H),2.13-2.06(m,1H),1.94 -1.79(m,4H),1.76-1.55(m,6H),1.41-1.22(m,14H),0.96-0.91(m,1H),0.85(s,3H).

[0245] Example-21: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl (compound 110) tetrahydro-1H-furo[3,4-c]pyrrole-5(3H)-carboxylate [ka] To a stirred solution of (7R,8R,95,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.45 g: prepared in step 1 of Example-6) in acetonitrile (10 mL), potassium carbonate (0.80 g) was added followed by 1'-methyl-[1,4'-bipiperidine]-4-amine (0.130 g). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was monitored by TLC (mobile phase: 70% ethyl acetate in n-hexane). After completion of the reaction (monitored by TLC), the mixture was diluted with water (30 mL) and extracted with ethyl acetate (3x150 mL). The combined organic layers were dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the crude material. The crude was purified by reverse phase HPLC [method: (A) 65% ammonium bicarbonate (B) 35% acetonitrile] and the product fraction was lyophilized to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yltetrahydro-1H-furo[3,4-c]pyrrole-5(3H)-carboxylate (93 mg, 21.4%) as a white solid.

[0246] LCMS: 99.28% (m / z: 744.30, [M+1]1, 6.73 min, 214 nm). 1H NMR(400MHz,DMSO-d6):δ7.28(d,J=8.40Hz,1H),6.85(d,J=8.40Hz,1H),6.82 (s.1H),3.80-3.69(m,3H),3.65-3.39(m,5H),3.25-3.27(m,1H),3.05-2.61( m,9H),2.46-2.34(m,4H),2.12-2.05(m,1H),1.94-1.83(m,4H),1.79-1.67(m ,3H),1.66-1.54(m,3H),1.44-1.14(m,14H),0.99-0.90(m.1H),0.84(s,3H).

[0247] Example-22: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(pyridin-4-yl)piperidine-1-carboxylate (Compound 116) [ka] To a stirred solution of 4-(piperidin-4-yl)pyridine (0.12 g) in acetonitrile (10 mL), potassium carbonate (0.21 g) was added and the resulting reaction mixture was stirred at room temperature for 2 hours. Thereafter, (7R,8R,9S,135,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-(4-nitrophenyl)carbonate (0.40 g, as prepared in Example-6, step-1) was added and the reaction mass was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mass was diluted with ice water (30 mL) and extracted with ethyl acetate (3X30 mL). The combined organic layers were washed with water (2×40 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 0.5 g of crude material. The crude material was purified by preparative HPLC using ammonium acetate as a buffer to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(pyridin-4-yl)piperidine-1-carboxylate (0.087 g, 21%) as a white solid.

[0248] LCMS: 95.25% (m / z:793.55, [M+1]+6.41 min, 214 nm). 1 H NMR(400MHz,DMSO-d6):δ8.49(dd,J=1.24.60Hz,2H),7.32(d,J=4.4Hz.2H),7.29(d ,J=8.8Hz,1H),6.88(d,J=6Hz,1H),6.85(s,1H),4.24-4.14(m,2H),3.11-2.86(m,2H) ),2.84-2.59(m,8H),2.50-2.32(m,5H),2.15-2.06(m,1H),1.94-1.80(m,6H),1.78 -1.48(m,8H),1.39-1.32(m,6H),1.25-1.17(m,8H),0.95-0.90(m,1H),0.84(s.3H).

[0249] Example-23: Preparation of (7R,8R,9S,13S,14S,Z)-17-hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (Compound 126)

[0250] Step-1: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (P1179-J03892-147): [ka] To a stirred solution of (7R,8R,9S,13S,14S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (1.0 g) in dichloromethane (20 mL) was added Dess-Martin Periodinane (0.635 g) and the resulting suspension was stirred at room temperature for 6 h. After completion of the reaction (monitored by TLC), the mixture was diluted with water (10 mL). The organic compounds were extracted with dichloromethane (3×70 mL), washed with water (2×200 mL) and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4′-bipiperidine]-1′-carboxylate (1.2 g, crude) as a colorless semi-solid.

[0251] LCMS: 80.82% (m / z:799.14, [M+1]+, 2.48 min (4 min run), 214 nm).

[0252] Step-2: Preparation of (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (1.2 g) in methanol (10 mL), sodium acetate (0.30 g) was added followed by hydroxylamine hydrochloride (0.25 g) and the resulting mixture was stirred at 60°C for 2 h. After completion of the reaction (monitored by TLC), the mixture was cooled to room temperature and diluted with ethyl acetate (50 mL). The combined organic layers were washed with water (2x200 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure to obtain the crude product. The crude material was purified by prep HPLC [Methods: (A) 25% ammonium bicarbonate (B) 70% acetonitrile] and the product fractions were lyophilized to give (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (compound 126, 270 mg, 22.5%) as a white solid.

[0253] LCMS: 95.96% (m / z: 814.55, [M+1]+, 6.13 min, (10 min run, 214 nm). 1 H NMR (400MHz, DMSO-d6): δ7.27(d,J=8.40Hz,1H),6.82(d,J=8.80Hz,1H),6.77(s.1H),4.21-4.12(m,2H),3.72-3.35(m,3H),3.10-2.81(m,5) H),2.74-2.67(m,3H),2.37-2.26(m,4H),2.04-2.07(m,2H),1.94-1. 84(m,5H),1.76-1.55(m,10H),1.53-1.10(m,20H),0.95-0.80(m,4H).

[0254] Example-24: Preparation of (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (Compound 138)

[0255] Step-1: Preparation of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (0.70 g) in dichloromethane (70 mL) was added Dess-Martin periodinane (0.44 g) and the resulting suspension was stirred at room temperature for 6 h. After completion of the reaction (monitored by TLC), the mixture was diluted with water (10 mL). The organic compound was extracted with dichloromethane (3x70 mL), washed with water (2x200 mL) and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (0.60 g, crude) as a yellow semi-solid.

[0256] LCMS: 38.61% (m / z:801.50)[M+1]+, 2.41 min (4 min run), 214 nm).

[0257] Step-2: Preparation of (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (0.60 g) in methanol (10 mL) was added sodium acetate (0.153 g) followed by hydroxylamine hydrochloride (0.124 g) and the resulting reaction mixture was stirred at 60° C. for 2 h. After completion of the reaction (monitored by TLC), the mixture was cooled to room temperature and diluted with ethyl acetate (30 mL). The combined organic layers were washed with water (2×200 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure to obtain the crude product. The crude material was purified by preparative HPLC using ammonium bicarbonate as a buffer, and the product fractions were lyophilized to give (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (155 mg, 25.4%) as a white solid.

[0258] LCMS: 99.37% (m / z: 816.60, [M+1]+, 6.04 min, 214 nm). 1 H NMR(400MHz,DMSO-d6-D2O):δ7.27(d,J=8.40Hz,1H),6.82(d,J=8.40Hz,1H),6 .77(s,1H),3.99-4.09(m,2H),3.57-3.55(m,4H),3.10-2.90(m,1H),2.87-2.6 1(m,7H),2.50-2.45(m,4H),2.39-2.35(m,7H),1.94-1.75(m,6H),1.71-1.68( m,2H),1.65-1.43(m,4H),1.39-1.10(m,17H),0.93-0.89(m,1H),0.85(s.3H).

[0259] Example-25: Preparation of (7R,8R,9S,135,14S)-17-(hydroxyamino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (Compound 151) [ka] To a stirred solution of (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5 pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (0.43 g) in 50% volume of acetic acid and tetrahydrofuran (5 mL), NaBH3CN (0.081 g) was added and the reaction mixture was stirred at room temperature for a further 8 h. After completion of the reaction (monitored by TLC), the mixture was diluted with ethyl acetate (50 mL). The combined organic layers were washed with water (2x200 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC using trifluoroacetic acid to give (7R,8R,9S,13S,14S)-17-(hydroxyamino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl[1,4'-bipiperidine]-1'-carboxylate (75 mg, 17.4%) as a white solid.

[0260] LCMS: 92.69% (m / z: 816.60[M+1]+, 5.47 min (10 min, 214 nm)).

[0261] 1 H NMR(400MHz,DMSO-d6):δ7.26(d,J=8.80Hz,1H),6.82(d,J=8.00Hz,1H),6.77(s,1H),4.10-4.21(m,2H),3.39-3.26(m,4H),3.01-2.79(m,6H),2. 76-2.62(m,4H),2.39-2.27(m,5H),2.03-2.05(m,4H),1.93-1.83(m,4H) ,1.69-1.56(m,12H),1.45-1.10(m,16H),0.84-0.87(m,1H),0.80(s,3H).

[0262] Example-26: Preparation of (7R,8R,9S,13S,14S)-17-(hydroxyamino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (Compound 163) [ka] To a stirred solution of (7R,8R,95,135,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (0.6 g, prepared in Example-24, step-1) in methanol (10 mL), sodium acetate (0.153 g) was added followed by hydroxylamine hydrochloride (0.124 g). After completion of the reaction (monitored by TLC), the mixture was cooled to room temperature and the reaction mixture was diluted with ethyl acetate (30 mL). The combined organic layers were washed with water (2x200 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure to give crude (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (0.600 mg, crude) as a semi-solid. The crude was carried forward without further purification.

[0263] LCMS: 56.93% (m / z: 816.10, [M+1]+, 2.48 min, 214 nm).

[0264] Step-3: Preparation of (7R,8R,9S,13S,14S)-17-(hydroxyamino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,Z)-17-(hydroxyimino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (0.6 g) in a mixture of acetic acid and tetrahydrofuran (5 mL and 5 mL), sodium triacetoxyborohydride (0.115 g) was added and the resulting reaction mixture was stirred at room temperature for 8 hours. After completion of the reaction (monitored by TLC), the mixture was extracted with ethyl acetate (50 mL). The combined organic layers were washed with water (2x200 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure to obtain the crude product. The crude material was purified by preparative HPLC to give (7R,8R,9S,13S,14S)-17-(hydroxyamino)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-1-carboxylate (500 mg, crude) as a colorless semi-solid.

[0265] LCMS:45.35%(m / z:818.03[M+1]+,2.49min,(4 min run, 214nm).

[0266] Example 27: Metabolic stability test of liver microsomes Metabolic stability studies were performed using rat liver microsomes (RLM) and human liver microsomes (HLM) under the following test conditions: microsomal protein concentration-0.5mg / mL, test substance concentration-1μM, NADPH concentration-1mM, time points-0, 5, 15, 30, 60 minutes. The assays were performed in duplicate.

[0267] Vials containing rat / human liver microsomes were removed from a -80±10°C freezer, thawed on an ice bath, and then suspended in 66.7 mM potassium phosphate buffer (pH 7.4). Test / reference compounds were added to the microsomes to prepare incubation mixtures. Aliquots were taken from the incubation mixtures into tubes labeled T0 (0 min), T5 (5 min), T15 (15 min), T30 (30 min), T60 (60 min), and TC (control, no NADPH). The incubation mixtures containing the tubes were then preincubated in a shaking water bath at 37±1°C for 5 min. At the same time, NADPH solution (10 mM) was also preincubated in a shaking water bath at 37±1°C for 5 min.

[0268] After preincubation, 20 μL of NADPH solution (10 mM) was added to the T5, T15, T30, and T60 tubes. Immediately after the addition of NADPH, 200 μL of quenching solution was added to stop the reaction in the TO tube. After preincubation, 20 μL of potassium phosphate buffer was added instead of NADPH to the TC (control, no NADPH) and incubated for 60 min.

[0269] After the incubation time for each tube (T5–T60) was completed, 200 μL of quenching solution was added to each tube to stop the reaction. The resulting samples were centrifuged at 3220 (relative centrifugal force) × g for 20 min. The supernatant (200 μL) from each reaction tube was taken for LC-MS / MS analysis. Verapamil and ketoconazole were used as reference compounds during the assay.

[0270] Bioanalysis was performed using LC-MS / MS.

[0271] Results - Compound 121 showed a half-life of 106 min in RLM and 44 min in HLM at the end of 60 min incubation. The half-lives of the reference compounds verapamil were 10 min in RLM and 11 min in HLM, and ketoconazole were 45 min in RLM and 120 min in HLM, demonstrating the validity of this study.

[0272] Table 2: Comparison of metabolic stability of compound 121 in rat and human liver microsomes [Table 2]

[0273] Example 28: CACO-2 Permeability Assay Permeability assays were performed using CACO-2 cell line obtained from ATCC. For the assay, cells were seeded on polycarbonate transwell filter membranes at a density of 60,000 cells / well. The medium was changed 24 hours after seeding and cells were cultured for an additional 21 days before treatment with test compounds. On the day of treatment, donor solutions were prepared by diluting stock solutions of test compounds in cell culture medium, i.e., 10 mM HEPES, pH 7.4 HBSS buffer. Receiver solutions contained blank 3% BSA (bovine serum albumin) in 10 mM HEPES, pH 7.4 HBSS buffer.

[0274] Transport of test compounds (15 μM) was measured in duplicate in two directions [apical to basolateral (A→B), basolateral to apical (B→A)].

[0275] The membrane permeability coefficient of the test compound was calculated by the following formula: Papp(cm / sec)=(Vr / C0) (1 / S) (dC / dt) (Papp = apparent permeability, Vr = volume of medium in the receiver chamber, CO = peak area ratio of the test drug in the receiver chamber, S = surface area of ​​the monolayer, dC / dt = change over time in the peak area ratio of the test drug in the receiver chamber).

[0276] Area of ​​24 wells = 0.7 cm 2 .

[0277] Peak area ratio = analyte peak area / IS peak area The efflux ratio was defined as Papp BA / Papp AB.

[0278] For receiver samples, an aliquot of 50 µL blank 3% BSA (bovine serum albumin) in 10 mM HEPES, pH 7.4 HBSS buffer was added to wells containing 50 µL of 3% BSA (bovine serum albumin) in 10 mM HEPES, pH 7.4 HBSS buffer spiked with test compound to match the matrix. For donor samples, an aliquot of 50 µL blank 3% BSA (bovine serum albumin) in 10 mM HEPES, pH 7.4 HBSS buffer spiked with test compound to match the matrix was added to wells containing 50 µL of 10 mM HEPES, pH 7.4 HBSS buffer spiked with test compound to match the matrix.

[0279] At the end of the time point (120 min for compound 121), the resulting samples were centrifuged at 3220 (relative centrifugal force) x g for 20 min and the supernatant (200 μL) was taken from each well for LC-MS / MS analysis.

[0280] The integrity of the monolayer was checked after the experiment, and the transfer of Lucifer Yellow across the membrane was less than 3%, confirming the integrity of the membrane. Standard compounds digoxin, atenolol, and propanolol were used at a final concentration of 5 μM.

[0281] Bioanalysis was performed using LC-MS / MS.

[0282] As a result, compound 121 had an AB transmittance of 7.26x10 -6 cm / sec, BA transmittance 4.20x10 -6 cm / sec, and the BA / AB ratio was 0.58.

[0283] The AB permeability of the reference compound, atenolol, is 2.18x10 -6 cm / sec, propranolol AB permeability is 62.15x10 -6 The BA / AB ratio of digoxin was 19.7, demonstrating the validity of this measurement method.

[0284] Table 3: Comparison of CACO-2 permeability of compound 121- [Table 3]

[0285] Example 29: Pharmacokinetic study in mice The purpose of this study was to evaluate the pharmacokinetic exposure of compound 121 after oral administration at a dose of 26 mg / kg to female CD-1 mice, as shown in Figure 1. The study was performed in female CD-1 mice that had been fasted for 6 hours. The dosage formulation was prepared fresh on the day of administration. 20% PG + 10% Solutol HS-15 + 70% PBS (pH 6.8) was used as the vehicle to prepare the dosage formulation.

[0286] Blood samples were collected by retro-orbital plexus puncture at 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after dosing (total of 9 time points / group: n=3 mice / time point / group). Approximately 0.150 mL of blood was collected at each time point and transferred to pre-labeled 0.5 mL microcentrifuge tubes containing 20 μL of 200 mM K2EDTA solution as anticoagulant and protease inhibitor cocktail (10% of collected blood volume). To facilitate mixing of the anticoagulant with the blood, the tubes were mixed gently by inversion. Blood samples were stored in gel packs and centrifuged immediately. Collected blood samples were centrifuged at 4000 rpm for 10 min at 4°C. After centrifugation, plasma was separated. All plasma samples were transferred to pre-labeled tubes and stored at -70±10°C until biological analysis. Blank plasma from naive mice was also collected using the same procedure as above, labeled as stabilized mouse blank plasma, and used for preparation of calibration standards / quality control samples / blank / zero standards during bioanalysis.

[0287] Bioanalysis was performed to quantify compound 121 in plasma using a tailored LC-MS / MS method. A calibration curve was constructed using stabilized blank mouse plasma in the range of 0.5-1000ng / mL. Samples were cleaned by protein precipitation and analyzed by LC-MS / MS.

[0288] Plasma pharmacokinetic parameters were calculated using standard noncompartmental analysis (linear trapezoidal method with linear interpolation).

[0289] Table 4: Arithmetic mean plasma pharmacokinetic parameters following a single oral dose of Compound 121 in female CD-1 mice. [Table 4]

[0290] Table 5: Arithmetic mean plasma concentrations of Compound 121 following a single oral dose to female CD-1 mice. [Table 5] NOTE: Values ​​are expressed as mean plus or minus SD.

[0291] Example 30: Cytotoxic effect of compound 121 on human breast cancer MCF-7 cells MCF-7 human breast cancer cells were obtained from American Type Culture Collection (ATCC, USA) and were cultured and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in a humidified incubator with 5% CO2. Cells were harvested when they reached 70-80% confluence using 0.25% trypsin-EDTA, seeded at 5000 cells / 200 μL / well in 96-well tissue culture-treated plates, and maintained in phenol-red Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (growth factor-deprived conditions). Approximately 24 hours after seeding, cells in the plates were treated in triplicate with nine concentrations of compound 121 (30000, 10000, 3000, 1000, 300, 100, 30, 10, and 3 nM). The plates were then incubated at 37°C and 5% CO2 for 5 days, with the medium replaced on the third day. Vehicle (0.1% DMSO concentration) was used for drug formulation. The negative control (MAX Viability) was medium (including cells) in the presence of 0.1% DMSO. The positive control (MIN Viability) was based on medium (including cells) in the presence of the highest concentration of paclitaxel (1 μM). After 5 days of treatment, cells were disrupted / lysed with Cell titer Glo (CTG) reagent. 40 μl was transferred to a luminescence plate and luminescence was recorded.

[0292] All statistical analyses were performed with Graph Pad Prism-9 software using four-parametric nonlinear regression analysis as shown in Figure 2. The IC50 value of compound 121 was reported as 362.3 nM.

[0293] Example 31. Effect of Compound 121 on Uterine Stimulating Activity in Sprague Dawley Juvenile Rats The study was carried out with immature female Sprague Dawley rats. The age of the animals at the time of randomization was 18 days. The rats were housed 3-4 per cage and maintained under controlled environmental conditions. All experimental animals used in this study followed a protocol approved by the International Animal Ethics Committee (IAEC), approval 057 / Jan-2020 No EAL-184_Utero_bioassay. Bedding was steam-sterilized corncobs (phytoestrogen-free) and was changed along with the cages at least once a week during the quarantine, acclimatization and test periods. All animals were fed ad libitum with a special rodent maintenance diet, Altromin (1334P phytoestrogen-free).

[0294] Compound 121 and vehicle were orally administered. The experiment started when the animals were 18 days old, which was considered as day 1 of administration. The animals were administered each administration group for 3 days from day 18 to day 20 after birth.

[0295] All animals were observed daily after dosing for abnormal clinical signs or mortality, and observations of individual animals were recorded during the dosing period.

[0296] The animals were sacrificed by gas anesthesia overdose; 24 hours after the last administration of compound (day 4). The uterus was carefully removed and the wet and dry weights were measured as shown in FIG.

[0297] Example 32: Anticancer effect of compound 121 in nude mice bearing MCF7 tumors. For this purpose, MCF7 cancer cells were procured from ATCC and cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-striptomycin. For tumor implantation, cells were harvested when they reached 70-80% confluence. 24 hours before MCF7 cell implantation, the skin around the injection site of nude mice was disinfected by gently wiping it with surgical spirit. 17β-estradiol pellets (0.18 mg / pellet for 60 days, Innovative Research of America) were implanted subcutaneously in the left flank of the animals. For cell inoculation, cells were mixed with an equal volume of Matrigel in a 1:1 ratio, and then 5x10 cells were inoculated into the left flank of the animals using a 1 mL syringe attached to a 24G needle. 6 MCF7 cells were injected subcutaneously into the right flank. Tumor palpability at the injection site was monitored over the following days. Tumor implants were assessed for tumor palpability within 7–8 days after cell inoculation. The tumor volumes of implanted animals were 200 ± 50 mm. 3 Once tumor volume reached 100 mg / kg, animals were randomized into different groups according to the study design based on tumor volume.

[0298] Randomization was performed so that the mean tumor volumes of each group were similar or not significantly different from each other. After randomization, the mean tumor volume was ∼200 ± 50 mm 3 Treatment was started when the tumor volume reached 100 mg / kg / day. Tumor volumes and mouse body weights were measured on the first day of treatment (day 1) and then three times a week for up to 28 days, as shown in FIG.

[0299] Compound 121 dose formulations (10, 30 and 60 mg / kg) and vehicle (0.5% MC) were administered orally daily for 28 days. Faslodex (Fulvestrant) was administered subcutaneously.

[0300] Tumor volume (mm 3 ) was calculated using the formula: tumor length × (tumor width)2 / 2. The tumor growth inhibition rate was calculated based on the value on day 1. TGI was calculated using the following formula. %TGI = [1-(mean TV of treatment) / mean TV of control] x 100

[0301] Table 6. Percent tumor growth inhibition (%TGI) at day 28 of different concentrations of compound 121 in MCF-7 xenograft mouse model.

[0302] [Table 6]

[0303] Example 33: Pharmacokinetic study in monkeys The purpose of this study is to evaluate the pharmacokinetics of Compound 121 administered orally at 25 mg / kg and Fulvestrant administered orally at 50 mg / kg in cynomolgus monkeys. The study was conducted in cynomolgus monkeys that were fasted overnight. The dose formulations shown in Figure 5 were prepared using 0.5% MC as a vehicle.

[0304] Blood samples were collected from the cephalic or saphenous vein into polyethylene microcentrifuge tubes containing potassium (K2) EDTA at 0 h (before dosing), 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, and 48 h after dosing. A total of 11 time points, n = 1 monkey. All blood samples were mixed by inversion and placed on wet ice until plasma was obtained. Blood samples were centrifuged at 3000 g for 10 min at 2–8°C to collect plasma. Approximately 200 μL of plasma sample from each time point was used for bioanalysis. Plasma samples were frozen and stored in a freezer kept at -60°C to 70°C until LC / MS / MS analysis.

[0305] Bioanalysis was performed using a fit-for-purpose LC-MS / MS method for quantification of compound 121 or fulvestrant in plasma samples. Calibration curves were constructed using stabilized blank monkey plasma in the range of 1-1000 ng / mL for compound 121 and 1-3000 ng / mL for fulvestrant. Samples were cleaned by protein precipitation and analyzed by LC-MS / MS.

[0306] Plasma pharmacokinetic parameters were calculated using standard noncompartmental analysis (linear trapezoidal method with linear interpolation).

[0307] Table 7: Arithmetic mean plasma pharmacokinetic parameters of Compound 121 and Fulvestrant following single oral administration to cynomolgus monkeys [Table 7]

[0308] Example-34: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-phenanthren-3-ylcyclopenta[a]phenanthren-3-yl(4aR,7aS)-4-methylhexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate

[0309] Step-1: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate [ka] To a stirred solution of fulvestrant (2.0 g) in acetonitrile (20 mL) at room temperature, cesium carbonate (3.24 g) and 4-nitrophenyl chloroformate (0.99 g) were added and stirred at the same temperature for 15 min. After completion of the reaction by TLC, the reaction was diluted with water (15 mL) and extracted with ethyl acetate (2x30 mL), the combined organic layers were dried over anhydrous sodium sulfate, and the organics were concentrated under reduced pressure to give 7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (2.3 g crude, LCMS 60%) which was used in the next step without further purification. LCMS purity: 60%

[0310] Step-2: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-phenanthren-3-yl (4aR,7aS)-4-methylhexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate [ka] To a stirred solution of (4aR,7aS)-4-methyloctahydropyrrolo[3,4-b][1,4]oxazine hydrochloride (0.110 g) in acetonitrile (10 mL), potassium carbonate (0.26 g) was added and stirred at room temperature for 2 hours. Then (7R,8R,9S,135,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-(4-nitrophenyl)carbonate (0.3 g) was added and the reaction mass was stirred at room temperature for 16 hours. After completion of the reaction by TLC, the reaction mass was diluted with ice water (15 mL) and extracted with ethyl acetate (3x30 mL), the combined organic layers were washed with water (2x100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude material was purified by preparative HPLC to obtain 0.28 g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4aR,7aS)-4-methylhexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate as a white solid.

[0311] LCMS purity: 98.33% 1H NMR(DMSO-do):δ7.27-7.23(m.1H),6.87-6.79(m,2H),4.59-4.53(bs,1H),4.25(bs,2H).415 -4.08(m,2H),3.94-3.85(m,1H),3.80-3.68(m,3H),3.61-3.55(m,6H),2.87-2.80(m,4H),2. 76-2.68(m,3H),2.65-2.62(m,1H),2.43-2.27(m,4H),1.94-1.88(m,3H),1.81(d,1H),1.70( d,1H),1.63-1.56(m,3H),1.58-1.48(m,1H),1.38-1.19(m,18H),0.90(bs,1H),0.67(s.3H).

[0312] Example-35: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-(trifluoromethyl)morpholine-4-carboxylate [ka] To a stirred solution of 2-(trifluoromethyl)morpholine hydrochloride (0.110 g) in acetonitrile (10 mL), potassium carbonate (0.26 g) was added and stirred at room temperature for 2 hours. Then (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-)pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.3 g, as prepared in Example-34, step-1) was added and the reaction mass was stirred at room temperature for 16 hours. After completion of the reaction as monitored by TLC, the reaction mass was diluted with ice water (15 mL) and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with water (2x100mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude material. The crude material was purified by preparative HPLC to give 0.10g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl). Pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-(trifluoromethyl)morpholine-4-carboxylate as a white solid.

[0313] LCMS purity: 99.52% 1 H NMR(DMSO-do): δ7.29(d,1H),6.87(d,1H),6.82(bs,1H),4.36(bs,1H),4.08-3.82( m,3H),3.71-3.65(t,1H),3.57-3.52(t,1H),3.13-3.10(bs,2H),2.90-2.80(m,2H) ,2.76-2.60(m,4H),2.40-2.25(m,5H),1.93-1.87(m,3H),1.79(d,1H),1.67(bs,1H) ),1.60-1.51(m,3H),1.47(bs,1H),1.39-1.11(m,18H),0.86(bs.1H),0.65(s,3H).

[0314] Example-36: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl tetrahydro-1H-furo[3,4-c]pyrrole-5(3H)-carboxylate [ka] To a stirred solution of hexahydro-1H-furo[3,4-c]pyrrole hydrochloride (0.086 g) in acetonitrile (10 mL), potassium carbonate (0.26 g) was added and stirred at room temperature for 2 hours. Then (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.3 g, as prepared in Example-34, step-1) was added and the reaction mass was stirred at room temperature for 16 hours. After completion of the reaction by TLC, the reaction mass was diluted with ice water (15 mL) and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with water (2x100mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material, which was purified by preparative HPLC to give 0.065g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yltetrahydro-1H-furo[3,4-c]pyrrole-5(3H)-carboxylate as a white solid.

[0315] LCMS purity: 99.52% 1H-NMR(DMSO-d6): δ7.26(d,1H),6.83(d,1H),6.78(bs,1H),2.95(bs,2H),2.87-2.80(m,2H),2.76-2.60(m,4H),2.43-2.37(m,2H),2.32-2.24( m,2H),1.94-1.86(m,3H),1.80(d,1H),1.70(d,1H),1.63-1.58(m,3H), 1.56-1.53(m,1H),1.38-1.17(m,19H),0.90-0.89(bs,1H),0.67(s.3H).

[0316] Example-37: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(3-((4,4,5,5,5-pentafluoropentyl)sulfinyl)propyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(2-oxopyrrolidin-1-yl)piperidine-1-carboxylate [ka] In a 25 mL round-bottom flask, (7R,8R,9S,135,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (0.7 g) was dissolved in acetonitrile (7 mL), then DIPEA (0.3 mL) and 4-nitrophenyl chloroformate (0.418 g) were added at a temperature of 0 ° C. In another 25 mL round-bottom flask, 1-(piperidin-4-yl)pyrrolidin-2-one hydrochloride (0.353 g) was dissolved in dichloromethane (7 mL), then DIPEA (0.2 mL) was added at room temperature. Both mixtures were stirred at the respective temperatures for 30 min. After 30 minutes of stirring, the second reaction mixture was added to the first reaction mixture at 0° C. and stirring was continued for 3.5 hours. After TLC and completion of the reaction, the reaction mass was diluted with water (25 mL) and extracted with dichloromethane (3×100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude material was purified by preparative HPLC to obtain 0.29 g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-4-(2-oxopyrrolidin-1-yl)piperidine-1-carboxylate as a white solid.

[0317] LCMS Purity: 99.00% 1 H NMR (DMSO-d6-D2O): δ7.25(d,1H),6.80(d.1H),6.75(s,1H),4.18-4.03(m,2H),3.93-3.95(m,1H),3.52(t,1H),3.30(t,2H),2.97-3.09 (m,1H),2.92-2.63(m,7H),2.39-2.21(m,7H),1.92-1.77(m,6H),1.66-1.45(m,9H),1.39-1.11(m,17H),0.86-0.80(m.1H),0.64(s,3H).

[0318] Example-38: Preparation of (7R,8R,9S,135,14S)-13-methyl-17-oxo-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(dimethylamino)piperidine-1-carboxylate

[0319] Step-1: Preparation of tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate [ka] To a stirred solution of tert-butyl 4-oxopiperidine-1-carboxylate (10 g) in dichloromethane (100 mL) was added acetic acid (3.01 g) and 2-aminoethan-1-ol (3 g) and the resulting reaction mixture was stirred for 30 minutes. Sodium triacetoxyborohydride (26.5 g) was then added to the above solution and the resulting reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction as monitored by TLC, the mixture was quenched with ice water (20 mL). The reaction was extracted with dichloromethane (3x200 mL) and then washed with water (2x500 mL). The organics were collected, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 7.5 g of tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate as a brown semi-solid.

[0320] 1 H NMR (DMSO-d6): δ4.41(bs,1H),3.80(d,2H),3.42(t,2H),2.89-2.59(m,2 H),2.56-2.59(m,2H),1.75-1.71(m,2H),1.38(s,9H),1.12-1.02(m,2H).

[0321] Step-2: Preparation of tert-butyl 4-(2-bromo-N-(2-hydroxyethyl)acetamido)piperidine-1-carboxylate [ka] To a stirred solution of (tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate (5.0 g) in tetrahydrofuran (50 mL) was added 2-bromoacetyl bromide (3.29 g) and the resulting mixture was stirred at -30°C for 5 minutes. After completion of the reaction monitored by TLC, the reaction mixture was quenched with cold water (10 mL). The reaction was extracted with ethyl acetate (3x80 mL) and then washed with water (2x500 mL). The organics were collected, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude was purified by CombiFlash chromatography to give 3.5 g of tert-butyl 4-(2-bromo-N-(2-hydroxyethyl)acetamido)piperidine-1-carboxylate as a yellow semi-solid. LCMS purity: 77.23%

[0322] Step-3: Preparation of tert-butyl 4-(3-oxomorpholino)piperidine-1-carboxylate [ka] To a stirred solution of tert-butyl 4-(2-bromo-N-(2-hydroxyethyl)acetamido)piperidine-1-carboxylate (3.) in tetrahydrofuran (50 mL) was added sodium hydride (0.276 g) and the resulting reaction mixture was stirred at room temperature for 1 h. After completion of the reaction as monitored by TLC, the reaction was quenched with cold water (10 mL). The reaction was extracted with ethyl acetate (3x100 mL) and then washed with water (2x200 mL). The organics were collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 2.7 g of tert-butyl 4-(3-oxomorpholino)piperidine-1-carboxylate as an off-white semi-solid.

[0323] LCMS purity: 96.88% 1H NMR (DMSO-d6): δ4.36(s,1H),4.12-4.02(m,4H),3.78(t,2H),3.23(t,2H),2.67-2.77(m,2H),1.58-1.50(m,4H),1.40(s,9H).

[0324] Step-4: Preparation of 4-(piperidin-4-yl)morpholin-3-one [ka] To a stirred solution of tert-butyl 4-(3-oxomorpholino)piperidine-1-carboxylate (2.6 g) in dichloromethane (5 mL), 4M hydrochloric acid in dioxane (5 mL) was added at a temperature of 0° C., and the resulting solution was stirred at room temperature for 2 hours. After completion of the reaction monitored by TLC, the mixture was concentrated under reduced pressure to obtain the crude material. The crude material was washed with diethyl ether and n-pentane to obtain 1.3 g of 4-(piperidin-4-yl)morpholin-3-one as a white solid.

[0325] LCMS purity: 99.62% 1 H NMR (DMSO-d6): δ4.48-4.46(m,1H),3.84-3.81(m,4H),3.31(d,2H),3.23(t,2H),3.03-2.97(m,2H),2.00-1.96(m,2H),1.67-1.70(m,2H).

[0326] Step-5: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(3-oxomorpholino)piperidine-1-carboxylate [ka] To a stirred solution of 4-(piperidin-4-yl)morpholin-3-one (0.437 g) in acetonitrile (15 mL), potassium carbonate (1.7 g) was added and the resulting reaction mixture was stirred at room temperature for 30 minutes. Then, (7R,8R,9S,135,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (1 g, prepared in Example-34, step-1) was added and the resulting mixture was stirred at room temperature for 4 hours. After completion of the reaction as monitored by TLC, the mixture was quenched with water (10 ml). The organic compound was extracted with ethyl acetate (3×50 mL), washed with water (2×200 mL), and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude material was purified using preparative HPLC to give 0.13 g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(3-oxomorpholino)piperidine-1-carboxylate as a white solid.

[0327] LCMS Purity: 99.30% 1 H-NMR (DMSO-d6-D2O):δ7.26(d,IH),6.81(d,1H),6.76(s,1H),4.44-4.37(m,1H),4.20-4.18(m,2H),4.02(s,2H),3.52(t,1H),3.26(t,2H),3.09- 2.88(m,2H),2.86-2.61(m,6H),2.40-2.21(m,3H),1.93-1.78(m,4H), 1.67-1.45(m,9H),1.37-1.13(m,19H),1.10-0.75(m,1H),0.64(s.3H).

[0328] Example-39: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate [ka] To a stirred solution of 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (0.622 g) in acetonitrile (12.5 mL) was added potassium carbonate (0.895 g) at 0° C., and the resulting reaction mixture was stirred for 15 minutes at 0° C. Then, (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (0.5 g, as prepared in Example-34, step-1) was added to the above reaction mixture, and the resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction as monitored by TLC, the mixture was diluted with water (10 mL). The reaction was extracted with ethyl acetate (3X10 mL) and then washed with water (2X10 mL). The organics were collected, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude material was further purified by preparative HPLC to give 0.32 g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate as a white semi-solid.

[0329] LCMS Purity: 99.98% 1 H NMR (DMSO-d6-D2O): δ7.28(d,1H),6.89(d,1H),6.84(s,1H),4.85-5.02(m,2H),4.24-4.27(m,2H),3.90-4.03(m,2H),3.52(t,1H) ,2.86-2.61(m,6H),2.40-2.22(m,3H),1.93-1.76(m,4H),1.69-1.45(m,5H),1.34-1.13(m,19H),0.84-0.86(m,1H),0.65(s,3H).

[0330] Example-40 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate [ka] To a stirred solution of compound-1 (0.3 g) in dichloromethane (4 mL) was added triphosgene (0.073 g) and DIPEA (6.84 g) at a temperature of 0° C. The resulting reaction mixture was stirred at 0° C. for 15 minutes. Then, tetrahydrothieno[3,2-c]pyridine (0.103 g) was added to the above solution and the resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction as monitored by TLC, the mixture was diluted with water (10 mL). The reaction was extracted with dichloromethane (3×10 mL) and washed with water (2×10 mL). The organics were collected, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude material. The crude material was purified by preparative HPLC to give 0.10 g of (7R,8R,95,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate as a white solid.

[0331] LCMS purity: 98.01% 1 H-NMR (DMSO-d6-D2O): δ7.29(d,1H),7.25(d,1H),6.88(d,1H),6.85(dd,1H),6.78(d,1H),4.68-4.50(m.2H),3.88-3.69(m,2 H),3.55(t,1H),2.89-2.79(m,4H),2.75-2.60(m,4H),2.40-2.25(m,3H),1.95-1.81(m.4H),1.70-1.43(m,5H),1.28(s,3H).

[0332] Example-41: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-(2-(trifluoromethyl)morpholino)phenyl)carbamate

[0333] Step-1: Preparation of 4-(4-nitrophenyl)-2-(trifluoromethyl)morpholine [ka] To a stirred solution of 1-fluoro-4-nitrobenzene (1.0 g) in dimethylformamide was added potassium carbonate (2.19 g) and 2-(trifluoromethyl)morpholine (1.95 g) at room temperature under nitrogen atmosphere. The resulting reaction mixture was stirred at 50° C. After completion of the reaction, monitored by TLC, the mixture was diluted with water and extracted with ethyl acetate. The organics were collected and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material. The crude material was purified by flash chromatography to give 0.70 g of 4-(4-nitrophenyl)-2-(trifluoromethyl)morpholine as a yellow solid. LCMS purity: 97.03%

[0334] Step-2: Preparation of 4-(2-(trifluoromethyl)morpholino)aniline [ka] To a stirred solution of 4-(4-nitrophenyl)-2-(trifluoromethyl)morpholine (0.7 g) in methanol (10 mL) was added 10% palladium on carbon (0.450 g, 50% wet basis) and the reaction mixture was stirred at room temperature under hydrogen atmosphere for 2.5 h. After completion of the reaction, monitored by TLC, the reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to give 0.6 g of 4-(2-(trifluoromethyl)morpholino)aniline as a brown sticky solid. LCMS purity: 79.16%

[0335] Step-3: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-phenanthren-3-yl(4-(2-(trifluoromethyl)morpholino)phenyl)carbamate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (1.2 g) in dichloromethane (20 mL) was added DIPEA (0.52 mL) and triphosgene (0.293 g) at 0 °C under nitrogen atmosphere. The resulting reaction mixture was stirred at the same temperature for further 10 min. Then, 4-(2-(trifluoromethyl)morpholino)aniline (0.585 g) was added to the above reaction while monitoring by TLC, and the reaction mixture was diluted with water and extracted with dichloromethane (2x100 mL). The organics were collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude material. The crude material was purified by preparative HPLC to obtain 0.70 g of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl-(4-(2-(trifluoromethyl)morpholino)phenyl)carbamate as a white solid.

[0336] LCMS purity: 95.01% 1H-NMR(DMSO-d6-D2O): δ7.32(d,2H),7.28(d,1H),6.95(d,2H),6.86(d, 1H),6.80(s,1H),4.34-4.14(m,1H),3.72(t,2H),3.59(d,1H),3.52(t,4 H),3.40(d,4H),2.78-2.59(m,7H),2.50-2.24(m,5H),1.88-1.77(m,4H ),1.66-1.46(m,5H),1.32-113(m,18H),0.87-0.84(m,1H),0.64(s,3H).

[0337] Example-42: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-oxo-[1,4'-bipiperidine]-1'-carboxylate

[0338] Step-1: Preparation of tert-butyl 2-oxo-[1,4'-bipiperidine]-1'-carboxylate: [ka] To a stirred solution of tert-butyl 4-oxopiperidine-1-carboxylate (2 g) in dichloroethane (40 mL) was added 5-aminopentanoic acid (2.92 g) and the resulting reaction mixture was stirred at room temperature for 16 hours. After the formation of imine was confirmed by TLC, sodium triacetoxyborohydride (3.18 g) was added to the above stirred solution. The resulting reaction mixture was stirred at room temperature for another hour. After 1 hour, triethylamine was added dropwise and the resulting reaction mixture was stirred at room temperature for another 14 hours and then heated at 60° C. for 60 hours. After completion of the reaction (monitored by TLC), the reaction mass was diluted with water (50 mL) and then extracted with dichloromethane (2×150 mL). The organic layer was washed with water (3×50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain tert-butyl 2-oxo-[1,4′-bipiperidine]-1′-carboxylate (2.5 g, crude) as a pale yellow gum. The product was used in the next step without purification. LCMS: 65.14% (m / z:227.31, [M-'Bu]+, 1.84 min (4 min run), 214 nm).

[0339] Step-2: Preparation of [1,4'-bipiperidin]-2-one hydrochloride [ka] To a stirred solution of tert-butyl 2-oxo-[1,4'-bipiperidine]-1'-carboxylate (3.) in dichloromethane (52 mL) was added 4M hydrochloric acid in 1,4-dioxane (17.5 mL) at 0°C under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mass was evaporated under reduced pressure to obtain the crude material. The crude material was triturated with n-pentane to obtain [1,4'-bipiperidine]-2-one hydrochloride (2.8 g) as an off-white solid. The crude material was carried forward to the next step without further purification.

[0340] 1H NMR (400MHz, DMSO-d6-D2O): δ4.43(t,1H),3.30(d,2H),3.12(t,2H),2.96-2.89(m,3H),2.22(t,2H),1.95-1.86(m,2H),1.66-1.62(m,6H).

[0341] Step-3: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-oxo-[1,4'-bipiperidine]-1'-carboxylate [ka] To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(4-nitrophenyl)carbonate (1.5 g, prepared in Example-34, step-1) in acetonitrile (20 mL) was added potassium carbonate (2.6 g) and [1,4'-bipiperidin]-2-one hydrochloride (0.635 g) at room temperature and the resulting reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction (monitored by TLC), the reaction was quenched with ice-cold water and extracted with ethyl acetate (3X75 mL). The collected organics were dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the crude material which was purified by preparative HPLC to give (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 2-oxo-[1,4'-bipiperidine]-1'-carboxylate (0.257 g, 16.2%) as a white solid.

[0342] LCMS: 99.38% (m / z:815.31, [M+1]+, 6.63 min (10 min run), 214 nm). 1 H NMR (400MHz, DMSO-d6-D2O): δ7.25(d,IH),6.81(d,1H),6.76(s,1H),4.44(t,IH),4.07-4.16(m,1H),3.52(t,1H),3.16-3.13(m,2H) ),3.11-3.01(m,1H),2.93-2.62(m,7H),2.43-2.28(m,3H),2.22(t,3H),1.93-1.78(m,4H),1.66-1.40(m,13H),1.34-1.14(m,19H).

[0343] Example-43: Preparation of (7R,8R,9S,138,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-phenanthren-3-ylcyclopenta[a]phenanthren-3-yl(2-ethylpyridin-4-yl)carbamate [ka] To a stirred solution of compound-1 (0.5 g) in dichloromethane (8 mL), DIPEA (0.52 mL) and triphosgene (0.12 g) were added at 0° C. and the resulting mixture was stirred at the same temperature for 10 min. Then, 2-ethylpyridin-4-amine (0.151 g) was added and the mixture was stirred at room temperature for 2.5 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (300 mL) and extracted with dichloromethane (2×500 mL). The organics were collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude material. The crude product was purified by preparative HPLC to give (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl))-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(2-ethylpyridin-4-yl)carbamate (0.145 g, 23.31%) as a white solid.

[0344] LCMS: 98.38% (m / z:755.26, [M+1]+, 6.29 min (10 min run), 214 nm). 1 H NMR (400MHz, DMSO-d6-D2O): δ8.49(d,1H),7.76-7.77(m,2H),7.35(d,1H),6.97(d,1H),6.93(s.1H),3.53(t,1H),2.92-2.63(m,8H) ),2.40-2.28(m,3H),1.93-1.79(m,4H),1.69-1.71(m,1H),1.60-1.47(m,4H),1.36-1.14(m,22H),0.85-0.87(m,1H),0.66(s,3H).

[0345] Example-44: Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(2-(trifluoromethyl)pyridin-4-yl)carbamate-9-carboxylate [ka] To a stirred solution of compound-1 (0.5 g) in dichloromethane (10 mL), DIPEA (0.21 mL) and triphosgene (0.12 g) were added at 0° C. and the reaction mixture was stirred at the same temperature for 10 min. 2-(trifluoromethyl)pyridin-4-amine (0.2 g) was added to the reaction mixture at a temperature of 0° C. and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mass was diluted with water (25 mL) and extracted with dichloromethane (2×25 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude material, which was purified by preparative HPLC to give (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl(2-(trifluoromethyl)pyridin-4-yl)carbamic acid-9-carboxylate (35 mg, 5.4%) as a white solid.

[0346] LCMS: 49.81+48.97% (m / z: 795.22, [M+1]+, 5.41 and 5.47 min (10 min run), 214 nm). 1 H NMR (400MHz, DMSO-d6-D2O, isomer mix): δ8.58(d.1H),8.07(d,1H),7.94(s,1H).7.67(d.1H),7 .33(d,1H),7.04(d,1H),6.95(d,1H),6.90-6.89(m,2H),6.66-6.65(m,1H),6.48-6.50(m.1H) ,6.41(s,1H),3.65-3.42(m,2H),2.86-2.61(m,11H),2.38-2.10(m,6H),1.93-1.75(m,6H),1. 75-1.46(m,8H),1.45-1.30(m,8H),1.25-1.13(m,20H),0.88-0.86(m,1H),0.63-0.66(m,4H).

[0347] Example 45: Cytotoxicity effects of compound (Ia) and compound (I-bh) on human breast cancer MCF-7 cells MCF-7 human breast cancer cells were obtained from American Type Culture Collection (ATCC, USA) and were cultured and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in a 5% CO2 humidified incubator. Cells were harvested when they reached 70-80% confluence using 0.25% trypsin-EDTA, seeded at 5000 cells / 200 μL / well in 96-well tissue culture treated plates, and maintained in phenol red Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (growth factor deficient conditions). Approximately 24 hours after seeding, the cells on the plates were treated in triplicate with 9 concentrations of compound (Ia) and compound (I-bh) (10000, 1000, 300, 100, 30, 10, 3, 1, 0.1 nM). The plates were then incubated at 37°C, 5% CO2 for 5 days, with the medium replaced on the third day.

[0348] Drug formulations were vehicle (0.1% DMSO concentration). Negative control (MAX Viability) was medium (including cells) in the presence of 0.1% DMSO. Positive control (MIN Viability) was medium (including cells) in the presence of the highest concentration of paclitaxel (1 μM). After 5 days of treatment, cells were disrupted / lysed with Cell titer Glo (CTG) reagent. 40 μl was transferred to a luminescence plate and luminescence was recorded.

[0349] All statistical analyses were performed with Graph Pad Prism-9 software using four-parametric nonlinear regression analysis as shown in Figures 6 and 7. The IC50 value of compound (Ia) was 11.15 nM, and the IC50 value of compound (I-bh) was 555.4 nM.

[0350] Example 46: Effect of compound (Ia) and compound (I-bh) on ER-α expression in human breast cancer MCF-7 cell line. MCF-7 human breast cancer cells were obtained from the American Type Culture Collection (ATCC, USA) and were cultured and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in a humidified 5% CO2 incubator. Cells were harvested when they reached 70-80% confluence using 0.25% Trypsin-EDTA. 3-4 days before drug administration, cells were maintained in growth factor deprivation at 37°C in a humidified 5% CO2 incubator. After 3-4 days, cells were trypsinized and seeded at 0.20*106 cells / well / mL in 24-well culture plates. Approximately 24 hours after seeding, five concentrations of compound (Ia) (100, 10, 1, 0.1, 0.01 μM) and compound (I-bh) (30, 10, 1, 0.1, 0.01 μM) were treated for 24 hours at 37°C and 5% CO2. Human MCF-7 cells were used as negative or vehicle controls. After 24 hours of treatment, the plates were washed with PBS and lysed with ~100 μL of RIPA buffer. Afterwards, the cell lysates were collected, and the supernatants were subjected to protein quantification by Bradford assay. Using 0.4 μg / μL (i.e. 0.4 mg / mL) of protein, simple Western ES (WES) was performed using a primary antibody (ER-a, 1:50 concentration) and a housekeeping gene (GAPDH, 1:2000 concentration). WES was performed in duplicate. After incubating the samples with the primary and secondary antibodies, chemiluminescence was measured.

[0351] For the vehicle and ER-α, the band area calculated by the software was analyzed. The ratio of ERα to the housing keep protein (GAPDH) was analyzed. The ratio was calculated relative to the vehicle control, and the graphs shown in Figures 8 and 9 were created.

[0352] Example 47: Pharmacokinetic data in rats The objective of this study was to evaluate the pharmacokinetic exposure following oral administration of Compound (Ia) or Compound (I-bh) at 10 mg / kg to female Sprague Dawley rats. The study was conducted in overnight fasted female Sprague Dawley rats. Dose formulations were prepared fresh on the day of dosing. 10% Solutol + 20% PG + 70% PBS was used as the vehicle to prepare the dose formulations.

[0353] Blood samples were collected by retro-orbital plexus puncture pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose. At each time point, blood was collected and transferred to pre-labeled microcentrifuge tubes containing anticoagulant. Tubes were gently mixed by inversion to facilitate mixing of the anticoagulant with the blood.All blood / plasma samples were analyzed using a tailored LC-MS / MS method. Pharmacokinetic parameters were calculated using standard non-compartmental analysis (Phoenix® software, version 8.3, Pharsight Corporation, Mountain View, CA, 94040 / USA) by the linear trapezoidal method with linear interpolation. See Figures 10 and 11.

[0354] Table 8: Arithmetic mean values ​​of pharmacokinetic parameters following oral administration of 10 mg / kg of Compound (Ia) or Compound (I-bh) in Sprague Dawley female rats. [Table 8]

[0355] Example 48: Anticancer effect of compound (Ia) in nude mice bearing MCF7 tumors For this purpose, MCF7 cancer cells were procured from ATCC and cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-striptomycin. For tumor implantation, cells were harvested when they reached 70-80% confluence. 24 h before MCF7 cell implantation, the skin around the injection site of nude mice was disinfected by gently wiping it with surgical spirit. 17β-estradiol pellets (0.18 mg / pellet for 60 days, Innovative Research of America) were implanted subcutaneously in the left flank of the animals. For cell inoculation, cells were mixed with an equal volume of Matrigel in a 1:1 ratio, and then 5x10 MCF7 cells were injected subcutaneously in the right flank using a 1 mL syringe attached to a 24 G needle. Tumor palpability at the injection site was monitored for the following days. Tumor implants were measured for tumor palpability within 7-8 days after cell inoculation. The tumor volume of implanted animals was 200 ± 50 mm 3 Once tumor volume reached 100 mg / kg, animals were randomized into different groups according to the study design based on tumor volume. Randomization was performed so that the mean tumor volumes of each group were similar or not significantly different from each other. After randomization, the mean tumor volume was ∼200 ± 50 mm 3 Treatment was started when the tumor volume and mouse body weight were measured on the first day of administration (day 1), and then three times a week until the 17th day.

[0356] Compound (Ia) (20 mg / kg) and vehicle (0.5% MC) were administered orally daily for 17 days. See FIG. Tumor volume (mm 3 ) was calculated by the formula: [tumor length × tumor width (2)] / 2. Tumor growth inhibition rate was calculated after normalizing the values ​​to those on day 1. TGI was calculated based on the following formula: %TGI = [1-(mean TV of treatment) / mean TV of control] x 100

[0357] Table 9. Tumor growth inhibition rate (%TGI) at 28 days with different concentrations of compound (Ia) in MCF-7 xenograft mouse model [Table 9]

Claims

1. Compounds of formula (I), their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates. [Formula 1] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; A is, [chemical 2] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C3] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C4] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C5] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C6] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C7] Here, R 14 teeth, [C8] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C9] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C10] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C11] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

2. Compounds of formula (IA), their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, or solvates. [C12] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected.

3. The compound according to claim 1, comprising compound (II) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C13] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, 【Chemistry 14】 Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) 【Chemistry 15】 Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) 【Chemistry 16】 Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at positions substitutable by radicals, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) 【Chemistry 17】 Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) 【Chemistry 18】 Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) 【Chemistry 19】 Here, R 14 teeth, 【Chemistry 20】 wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) 【Chemistry 21】 Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) 【Chemical 22】 Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) 【Chemistry 23】 Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

4. 2. The compound of claim 1, comprising a compound (III) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [C24] (wherein X and A have the same meanings as given for the compound of formula (II).)

5. 2. The compound of claim 1, comprising compound (IV) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C25] (wherein Y and A have the same meanings as given for the compound of formula (II).)

6. The compound according to claim 1, comprising compound (V) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C26] (In the formula; A is, [C27] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 are independently selected from the group consisting of i) to ix) below; i) [C28] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C29] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C30] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C31] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C32] Here, R 14 teeth, [C33] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C34] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C35] Here, R 16is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C36] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

7. 2. The compound of claim 1, comprising compound (VI) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C37] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [C38] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C39] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C40] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 are taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at positions substitutable by radicals, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C41] Here, each R 12is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C42] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C43] Here, R 14 teeth, [C44] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C45] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C46] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C47] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

8. The compound according to claim 1, comprising compound (VII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C48] (wherein X and A have the same meanings as given for the compound of formula (VI).)

9. 2. The compound of claim 1, comprising a compound (VIII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C49] wherein Y and A have the same meanings as given for the compound of formula (VI).

10. The compound according to claim 1, comprising compound (IX) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [50] (Wherein, A is [C51] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C52] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C53] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C54] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C55] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C56] Here, R 14 teeth, [C57] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C58] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C59] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [60] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

11. The compound according to claim 1, comprising a compound (X) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [61] wherein X is a halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [62] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [63] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [64] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [65] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [66] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [67] Here, R 14 teeth, [68] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [69] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C70] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C71] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

12. The compound according to claim 1, comprising compound (XI) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C72] (wherein X and A have the same meanings as given for the compound of formula (X).)

13. The compound according to claim 1, comprising compound (XII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C73] (wherein Y and A have the same meanings as given for the compound of formula (X).)

14. The compound according to claim 1, comprising a compound (XIII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C74] (In the formula; A is, [C75] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C76] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C77] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C78] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C79] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C80] Here, R 14 teeth, [chemical 81] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [chemical 82] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [chemical 83] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [chemical 84] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

15. The compound according to claim 1, comprising a compound (XIV) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C85] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [chemical 86] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [chemical 87] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkalkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C88] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C89] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C90] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C91] Here, R 14 teeth, [C92] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C93] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C94] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C95] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

16. The compound according to claim 1, comprising a compound (XV) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C96] (wherein X and A have the same meanings as given for the compound of formula (XIV).)

17. 2. The compound according to claim 1, comprising compound (XVI) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C97] wherein Y and A have the same meaning as given for the compound of formula (XIV).

18. 2. The compound according to claim 1, comprising a compound (XVII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C98] (In the formula; A is, [C99] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C100] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C101] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C102] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [chemical 103] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C104] Here, R 14 teeth, [C105] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C106] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C107] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C108] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

19. 2. The compound according to claim 1, comprising a compound (XVIII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C109] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; A is, [C110] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C111] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C112] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C113] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C114] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C115] Here, R 14 teeth, [C116] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C117] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C118] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C119] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

20. The compound according to claim 1, comprising a compound (XIX) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C120] (wherein X and A have the same meanings as given for the compound of formula (XVIII).)

21. The compound according to claim 1, comprising a compound (XX) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C121] wherein Y and A have the same meaning as given for the compound of formula (XVIII);

22. 2. The compound of claim 1, comprising compound (XXI) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C122] (In the formula; A is, [C123] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C124] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C125] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C126] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C127] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C128] Here, R 14 teeth, [C129] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C130] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C131] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C132] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

23. The compound according to claim 1, comprising a compound (XXII) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C133] (In the formula; A is, [C134] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C135] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C136] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C137] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C138] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C139] Here, R 14 teeth, [C140] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C141] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C142] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C143] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

24. The compound according to claim 1, comprising a compound represented by the following formula (XXIII), a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [C144] (wherein X and A have the same meanings as given for the compound of formula (XXII).)

25. 2. The compound of claim 1, comprising the compound (XXIV) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C145] (wherein Y and A have the same meanings as given for the compound of formula (XXIV).)

26. 2. The compound of claim 1, comprising a compound (XXV) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C146] (In the formula; A is, 【Chemistry 147】 Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) 【Chemistry 148】 Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7 Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) 【Chemistry 149】 Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) 【Chemistry 150】 Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) 【Chemistry 151】 Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) 【Chemistry 152】 Here, R 14 teeth, 【Chemistry 153】 wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) 【Chemistry 154】 Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) 【Chemistry 155】 Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) 【Chemistry 156】 Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

27. 2. The compound according to claim 1, comprising the compound (XXVI) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C157] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single bond or a double bond depending on the substituents selected; a is selected from carbon or nitrogen; Q is selected from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl.

28. The compound according to claim 1, comprising a compound (XXVII) represented by the following formula: [C158] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; Here, R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, and one or more R 7 is substituted at any position substitutable by a radical, where one or more R 7The radicals are independently selected at each occurrence from the group consisting of substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, phosphonyl, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; preferably, the radical R 7 The one or more substituents above are further substituted with one or more selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, phosphate, alkylphosphate.

29.

159. (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; S is selected from O, C, or N; and R 7 is selected from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl.

30. 2. The compound according to claim 1, comprising a compound represented by the following formula (XXIX), a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C160] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; R 4 ' is selected from the group consisting of hydrogen and optionally substituted alkyl; R 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

31. R 4 and optionally substituted substituents on R4', said substituents being selected from the group consisting of radicals such as C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, dialkylaminoacyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, haloalkyl, cyano, hydroxy, mercapto, nitro, phosphate, oxo, alkylphosphate, and the like.

32. 2. The compound of claim 1, comprising a compound represented by the following formula (XXX), a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof: [C161] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; d is selected from carbon or nitrogen; where R15 and R16 taken together form an optionally substituted carbocyclic or heterocyclic structure; m and n can independently be 1 to 3.

33. 33. The compound of claim 32, wherein compound (XXX) is optionally substituted with substituents selected from the group consisting of alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, and alkoxyalkyl.

34. 2. The compound of claim 1, comprising the compound (XXXI) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C162] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single bond or a double bond depending on the substituents selected; D is selected from an optionally substituted bicyclic, spirocyclic or bridged bicyclic compound, and the attachment of the bicyclic, spirocyclic or bridged bicyclic compound is through either a carbon atom or a nitrogen atom.

35. A compound selected from the group consisting of the formulae set forth in Table 1 below. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15]

36. Compounds of formula (I), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts, or solvates; and A pharmaceutical composition comprising a pharma- ceutically acceptable excipient.

37. A prodrug of fulvestrant of formula (IA), its enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts, or solvates; and A pharmaceutical composition comprising a pharma- ceutically acceptable excipient.

38. A method for treating a benign or malignant disease of the breast or reproductive tract, preferably a method for treating breast cancer, comprising administering a compound of formula (I) or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C163] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected; A is, [C164] Or -O-R 2 where R 1 is selected from hydrogen or alkyl; R 2 is independently selected from the group consisting of i) to ix) below: i) [C165] Here, R 3 NH 2 , N.H.R. 4 , or N.R. 5 R 6 is selected from; 4 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 5 and R 6 are independently selected from the group consisting of optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl; or R 5 and R 6 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycle, optionally with one or more R 7 may be substituted at any position substitutable by a radical, where one or more R 7Radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro, amino, hydroxyalkylamino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl; ii) [C166] Here, R 8 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 9 R 10 wherein R 9 and R 10 taken together with the carbon to which they are attached, up to four carbon atoms are replaced with heteroatoms selected from the group consisting of O, S or N, and optionally one or more R 11 Form a 3- to 7-membered saturated, partially unsaturated or unsaturated heterocyclic ring, optionally substituted at any position substitutable by a radical, where one or more R 11 The radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl, alkylthio, arylcarbonyl; iii) [C167] Here, each R 12 is independently selected from hydrogen; optionally substituted alkyl, aryl, acyl, heterocycloalkyl, or heteroaryl; iv) [C168] Here, each R 13 is independently selected from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; v) an amino acid, where the amino acid is attached at the attachment point via an ester bond; vi) [C169] Here, R 14 teeth, [C170] wherein m and p are independently selected from 0 to 5, n represents the degree of polymerization and is selected from 1 to 250, and Z is an optionally substituted alkyl or cycloalkyl; vii) [C171] Here, R 15 is selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; viii) [C172] Here, R 16 is selected from the group consisting of hydrogen; optionally substituted alkyl, aryl, acyl, heteroaryl; and X is optionally substituted heterocycloalkyl; ix) [C173] Here, R 17 is selected from an optionally substituted bicyclic, spirocyclic, or bridged bicyclic compound.

39. A method of treating a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer, comprising administering a compound of formula (IA), a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C174] (In the formula; X is halogen or hydrogen; Y is alkyl, -O-alkyl or hydrogen; Z is selected from =O, =N-OH, -O-alkyl, -O-haloalkyl, -NH-OH or -O-alkyl-OH, and the bond between the Z substituents attached to the carbon can be a single or double bond depending on the substituents selected.

40. Compounds of formula (A), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates. [C175] (In the formula; R' 1 is an optionally substituted heterocycloalkyl, heteroaryl, and [C176] wherein one or more of the substituents on the optionally substituted heterocycloalkyl, heteroaryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R' 2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl and aryl groups, where one or more substituents on the heterocycloalkyl, heteroaryl and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo and oxo groups, where one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo and oxo groups.

41. In formula (A), R' 2 41. The compound of claim 40, wherein is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C177] .

42. In formula (A), R' 1 is an optionally substituted heterocycloalkyl or heteroaryl selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof; [C178] [C179]

43. Compounds of formula (B), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates. [C180] (In the formula; R 1 ' is selected from: [C181] Here, R' 2 is selected from the group consisting of optionally substituted heterocycloalkyl groups, heteroaryl groups, and aryl groups; wherein the one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups; wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; [C182] represents an aromatic ring; X is independently N, O, S, [C183] Selected from: Here, R 3 , R. 4 , R 3 ', R 4are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 ', together with the atoms to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R' 5 may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C184] Form.

44. Compounds of formula (C), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates. [C185] (In the formula; R 1 ' is selected from: [C186] R 2 ' is selected from: [C187] During the ceremony, [C188] represents an aromatic ring; [C189] represents saturated, partially unsaturated, or fully unsaturated ring: X is independently N, O, S, [C190] Selected from: Y is C, [C191] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, where the remaining atoms in the ring are carbon and each heteroatom is independently selected from nitrogen, oxygen, and sulfur, and ring A represents one or more R" independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. 6 optionally substituted with radicals, wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; Here, R 3 , R. 4 , R 3 ', R 4are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C192] Form.)

45. 45. The compound of claim 44, including a compound of formula (D) below, an enantiomer, a diastereomer, a racemate, a pharma- ceutically acceptable salt or a solvate thereof: [C193] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; Or each R 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 form a double bond together with the atoms to which they are attached; or each R" 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C194] Form.)

46. 46. ​​The compound of claim 45, which is a compound selected from the group consisting of the following formulas, an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof: [C195]

47. 45. The compound according to claim 44, comprising a compound (E) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C196] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C197] Form.)

48. 45. The compound according to claim 44, comprising a compound (F) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C198] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C199] Form.)

49. 45. The compound according to claim 44, comprising compound (G) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [chemical 200] (In the formula;, R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [chemical 201] Form.)

50. 50. The compound of claim 49, comprising a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C202]

51. 45. The compound of claim 44, comprising compound (H) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C203] (In the formula; R” 3 , R. 4 , R 3 ', R 4are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C204] Form.)

52. 52. The compound of claim 51, selected from the group consisting of: their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts or solvates. [C205]

53. The compound according to claim 44, comprising a compound (W) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C206] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3' and R 4 ' are joined together by an oxo bond [C207] Form.)

54. 45. The compound according to claim 44, comprising compound (J) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C208] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C209] Forming .

55. 55. The compound of claim 54, which is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C210]

56. 45. The compound according to claim 44, comprising a compound (K) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof: [C211] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C212] Form.)

57. 57. The compound of claim 56, which is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C213] [C214]

58. 45. The compound according to claim 44, comprising a compound (L) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C215] R” 3 , R. 4 , R 3 ', R 4are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C216] Form.)

59. 59. The compound of claim 58, which is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C217] [C218]

60. 45. The compound according to claim 44, comprising a compound (M) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C219] (In the formula; R” 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; Or, each R 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; Or, each R 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C220] Forming .

61. 61. The compound of claim 60, which is a compound selected from the group consisting of: an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C221]

62. 45. The compound according to claim 44, comprising compound (N) represented by the following formula: or an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof. [C222] (In the formula; The solid circle represents an aromatic ring; X is independently N, O, S, [C223] Selected from: Each R" is independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

63. 45. The compound of claim 44, including a compound (O) represented by the following formula: [C224] The solid circle represents an aromatic ring; X is independently N, O, S, [C225] Selected from: R” 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

64. 64. The compound of claim 63, which is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C226]

65. 45. The compound of claim 44, comprising a compound (P) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C227] The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [C228] selected from N, O and S; R” 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

66. 66. The compound of claim 65, which is a compound represented by the formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C229] .

67. The compound according to claim 44, comprising a compound (Q) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C230] (In the formula;, The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [C231] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, where the remaining atoms of the ring are carbon and each heteroatom is independently selected from nitrogen, oxygen, and sulfur, and ring A represents one or more R" independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. 6 optionally substituted with radicals, wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R” 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

68. 68. The compound of claim 67, which is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C232]

69. 45. The compound of claim 44, comprising a compound (R) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C233] (In the formula; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [C234] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, where the remaining atoms in the ring are carbon and each heteroatom is independently selected from nitrogen, oxygen, and sulfur, and ring A represents one or more R" independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. 6 optionally substituted with radicals, wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R” 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

70. 45. The compound of claim 44, comprising a compound (S) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C235] Where: The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [C236] selected from N, O and S; R” 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

71. 71. The compound of claim 70, which is a compound selected from the group consisting of: a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C237] [C238]

72. 45. The compound of claim 44, comprising a compound (T) represented by the following formula: or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, or solvate thereof. [C239] (In the formula, The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [C240] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, where the remaining atoms in the ring are carbon and each heteroatom is independently selected from nitrogen, oxygen, and sulfur, and ring A represents one or more R" independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. 6 optionally substituted with radicals, wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R” 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

73. The compound of claim 44, comprising a compound (U) represented by the following formula: [C241] Where: The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: Y is C, [C242] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, where the remaining atoms of the ring are carbon and each heteroatom is independently selected from nitrogen, oxygen, and sulfur, and ring A represents one or more R" groups independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. 6 optionally substituted with radicals, wherein one or more of the substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R” 4are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; .

74. The following formula: [C243] [C244] [C245] [C246] [C247] [C248] A compound selected from the group consisting of: an enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate thereof.

75. Compounds of formula (A), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts, or solvates; and A pharmaceutical composition comprising a pharma- ceutically acceptable excipient.

76. Compounds of formula (B), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts, or solvates; and A pharmaceutical composition comprising a pharma- ceutically acceptable excipient.

77. Compounds of formula (C), their enantiomers, diastereomers, racemates, pharma- ceutically acceptable salts, or solvates; and A pharmaceutical composition comprising a pharma- ceutically acceptable excipient.

78. A method for treating a benign or malignant disease of the breast or reproductive tract, preferably breast cancer, which comprises administering a compound of formula (A), its enantiomer, diastereomer, racemate, pharma- ceutically acceptable salt or solvate. [C249] (In the formula; R' 1 is an optionally substituted heterocycloalkyl, heteroaryl, and [C250] wherein one or more of the substituents on the optionally substituted heterocycloalkyl, heteroaryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; R' 2 is selected from the group consisting of optionally substituted heterocycloalkyl, heteroaryl, and aryl, where one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups, where one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups.

79. A method for treating a benign or malignant disease of the breast or reproductive tract, preferably breast cancer, which comprises administering a compound of formula (B), an enantiomer, a diastereomer, a racemate, a pharma- ceutically acceptable salt or a solvate thereof. [C251] (In the formula; R 1 ' is selected from: [C252] Here, R' 2 is selected from the group consisting of optionally substituted heterocycloalkyl groups, heteroaryl groups, and aryl groups; wherein the one or more substituents on the heterocycloalkyl, heteroaryl, and aryl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; The solid circle represents an aromatic ring; X is independently N, O, S, [C253] Selected from: Here, R 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or each R" 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [C254] Form.)

80. A method for treating a benign or malignant disease of the breast or reproductive tract, preferably breast cancer, which comprises administering a compound of formula (C), an enantiomer, a diastereomer, a racemate, a pharma- ceutically acceptable salt or a solvate thereof. [C255] (In the formula; R 1 ' is selected from: [C256] R 2 ' is selected from: [C257] The solid circle represents an aromatic ring; The dashed circles represent saturated, partially unsaturated, or fully unsaturated rings: X is independently N, O, S, [C258] Selected from: Y is C, [C259] selected from N, O and S; Fused ring A represents an optionally substituted saturated, unsaturated, or aromatic 4-, 5-, 6-, or 7-membered ring having zero or more heteroatoms in the ring, where the remaining atoms in the ring are carbon and each heteroatom is independently selected from nitrogen, oxygen, and sulfur, and ring A represents one or more R" independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, halo, and oxo groups. 6 optionally substituted with radicals, wherein the one or more substituents on the substituted heterocycloalkyl are selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; Here, R 3 , R. 4 , R 3 ', R 4 are each independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, heterocycloalkyl, substituted heterocycloalkyl, and halo groups, where the substituted heterocycloalkyl has one or more substituents selected from alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ', or R" 3 and R. 4 , or R 3 ' and R 4 R′, taken together with the atom to which they are attached, form a 3- to 7-membered saturated, partially unsaturated or unsaturated ring which may contain one or more heteroatoms selected from N, O and S, and the ring may optionally be joined by one or more R′ 5 It may be substituted at any position substitutable by a radical, where one or more R' 5 The radicals are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, amino, alkylamino, dialkylamino, halo, and oxo groups; or Each R” 3 and R 3 ', or R" 4 and R 4 ' together with the atoms to which they are attached form a double bond; or Each R” 3 and R. 4 , or R 3 ' and R 4 ' are joined together by an oxo bond [chemical 260] Form.)

Citation Information

Patent Citations

  • Prodrugs of fulvestrant

    WO2021100029A2